EurekaMag Full Text Articles Chapter 34,513

Osorio, C.; Duque, C.; Fujimoto, Y. 1999: C13-norisoprenoid glucoconjugates from lulo leaves. Journal of Agricultural and Food Chemistry 47(4): 1641-1645

Duque, C.; Osorio, C.; Morales, A.L. 2000: C13-norisoprenoids in the aroma of Colombian tropical fruits. Abstracts of Papers American Chemical Society 219(1-2): AGFD 45

Schwarz, S.; Muller, G.; Kosemund, D.; Richter, M.; Peters, O.; Scherlitz Hofmann, I.; Michel, T.; Elger, W.; Reddersen, G.; Schneider, B. 2003: C13-substituted estra-1,3,5, -trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds. Official Gazette of the United States Patent and Trademark Office Patents 1271(4)

Vandekerckhove, Tom; Boon, Paul A.J.M.; Van Laere, Koen; Je Vonck, Kristl; Dierckx, Rudy; De Reuck, Jacques 2000: C15O2-positron emission tomography activation study in patients treated with vagus nerve stimulation for refractory epilepsy. Epilepsia 41(Suppl 7): 38

Delong, M.A.; Soper, D.L.; Wos, J.A.; De, B. 2002: C16 unsaturated FP-selective prostaglandins analogs. Official Gazette of the United States Patent and Trademark Office Patents 1262(3)

Ding, Z.; Jin, J.; Kim, S.; Kunapuli, S.P. 2002: C17 and C270 on Human Platelet P2Y12 Receptor Are the Target of Clopidogrel. Blood 100(11): Abstract No. 966

Contzler, R.; Uhlmann, M.; Panizzon, R.; Huber, M.; Hohl, D. 2003: C1orf1O, a novel marker of late terminal keratinocyte differentiation. Journal of Investigative Dermatology 121(1): 0479

Williams, Y.; Feighery, C.; Abuzakouk, M. 2003: C1q autoantibodies: cause or effect of recurrent infection. Lupus 12(10): 795-797

Robson, M.G.; Cook, H.T.; Botto, M.; Taylor, P.R.; Carroll, M.C.; Pusey, C.D.; Walport, M.J.; Davies, K.A. 1999: C1q deficiency exacerbates accelerated nephrotoxic nephritis. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 520A

Webster, S.D.; Galvan, M.D.; Tenner, A.J. 2000: C1q enhances antibody-mediated uptake of the amyloid beta-peptide by microglia. Immunopharmacology 49(1-2): 15

Bai, Y.nhong; Pachner, Andrew, R.; Cadavid, Diego 2003: C1q expression increases in the central and peripheral nervous system during neuroborreliosis. Annals of Neurology 54(Suppl 7): S49

Taylor, P.R.; Ogden, C.; Fadok, V.; Andrews, M.; Savill, J.; Cook, H.T.; Henson, P.; Botto, M.; Walport, M.J. 1999: C1q is required for the efficient phagocytic clearance of apoptotic cells in vivo. Molecular Immunology 36(4-5): 308

Stuart, L.M.; Clay, M.; Savill, J.; Lacy Hulbert, A. 2003: C1q mediates in vivo clearance of apoptotic cells from the systemic circulation by CD11c positive splenic dendritic cells. Journal of the American Society of Nephrology 14(Abstracts Issue): 162A

Ogden, C.A.; Ghebrehiwet, B.; Fadok, V.; Henson, P. 2000: C1q mediates the clearance of apoptotic cells. Immunopharmacology 49(1-2): 40

Eggleton, P.; Tenner, A.J.; Reid, K.B. 2000: C1q receptors. Clinical and Experimental Immunology 120(3): 406-412

Lynch, N.J.; Guerin, C.J.; Roscher, S.; Willis, C.; Nolan, C.C.; Ray, D.E.; Schwaeble, W.J. 2002: C1q synthesis in the brains of S-chlorohydrin-treated rats. International Immunopharmacology 2(9): 1301

Meehan, W.P.; Knitter, G.H.; Lasser, G.W.; Lewis, K.; Ulla, M.M.; Bishop, P.D.; Hanson, S.R.; Fruebis, J. 2002: C1q-TNF Related Protein-1 Prevents Thrombus Formation in Non-Human Primates and Atherosclerotic Rabbits without Causing Bleeding. Blood 100(11): Abstract No. 75

Meehan, W.P.; Knitter, G.; Lasser, G.; Lewis, K.; Marzec, U.M.; Bishop, P.; Hanson, S.R.; Fruebis, J. 2002: C1q-TNF Related Protein-1 prevents thrombosis without affecting hemostasis. Circulation 106(19): II119

Fruebis, J.; Knitter, G.H.; Meehan, W.P.; Meredith, C.; Gray, J.; Ellsworth, J.L.; Bishop, P.D. 2003: C1q-TNF related protein-1 a promising novel approach to prevent platelet thrombosis. Blood 102(11): 809a

Nicholson-Weller, A.; Klickstein, L.B. 1999: C1q-binding proteins and C1q receptors. Current Opinion in Immunology 11(1): 42-46

Pfuller, B.; St Blass; Rathmann, J.; Nitsch, S.; Burmester, G.R.; Hiepe, F. 1999: C1q-dependent inhibition of T cell proliferation is impaired in SLE patients. Arthritis and Rheumatism 42(9 Suppl): S104

Tyagi, S.; Barbashov, S.F.; Klickstein, L.B.; Nicholson Weller, A. 1999: C1q-stimulated superoxide generation Functional roles of CR1 and CR3. FASEB Journal 13(4 Part 1): A282

Bordin, S.; Whitfield, D. 2002: C1q-tails activate p38 MAPK and apoptosis in fibroblasts. International Immunopharmacology 2(9): 1312-1313

Bohlson, S.S.; Zhang, M.; Ortiz, C.; Tenner, A.J. 2002: C1qRP interacts with the PDZ domain containing protein GIPC via a class 1 PDZ binding motif. International Immunopharmacology 2(9): 1279-1280

Ligoudistianou, C.; Garnier, G.; Circolo, A.; Volanakis, J.E. 2002: C1r-like protein A novel human complement-related protein. International Immunopharmacology 2(9): 1267-1268

Rossi, V.; Teillet, F.; Bally, I.; Arlaud, G.J. 2002: C1s/MASP-2 chimeras Tools to determine the relative contributions of the CCP modules and serine protease domain of MASP-2 to its higher C4 cleaving activity. International Immunopharmacology 2(9): 1253

Fiocchi, R.; Gamba, A.; Iamele, L.; Ferrazzi, P. 2002: C2 blood levels in pediatric heart transplanted patients. Journal of Heart and Lung Transplantation 21(1): 63

Soubra, S.H.; Vernarske, D.; Bag, R.; Frost, A.E. 2002: C2 cyclosporine levels correlates best with area under the curve in pancreatic insufficient cystic fibrosis patients. Journal of Heart and Lung Transplantation 21(1): 85

Mantilla, C.B.; Zielinska, W.; Zhan, W.Z.; Sieck, G.C. 2002: C2 hemisection alters Trk B and NT-4/5mRNA expression in both diaphragm muscle and spinal cord. FASEB Journal 16(5): A771

Weber, L.T.; Shipkova, M.; Armstrong, V.W.; Mehls, O.; Oellerich, M.; Tönshoff, B. 2003: C2 monitoring and absorption profiling of cyclosporine for optimization of immunosuppressive therapy in pediatric renal transplant recipients. Transplantation Proceedings 35(6): 2128-2130

Baraldo, M.; Francesconi, A.; Barbone, F.; Tursi, V.; Livi, U.; Furlanut, M. 2002: C(2) monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses. Transplantation Proceedings 34(8): 3246-3248

Dorizzi, R.M.; Boschiero, L.; Meneghelli, S.; Caputo, M.; Mazzoni, M.; Rizzotti, P. 2003: C2 monitoring of long term renal transplant recipients using Dimension RxL 18 months experience. Clinical Chemistry 49(S6): A78

Golder, F.J.; Davenport, P.W.; Johnson, R.D.; Reier, P.J.; Bolser, D.C. 2002: C2 spinal hemisection and unilateral phrenicotomy have a similar effect on the breathing pattern. FASEB Journal 16(4): A67

Golder, F.J.; Davenport, P.W.; Johnson, R.D.; Reier, P.J.; Bolser, D.C. 2002: C2 spinal hemisection increases augmented breath frequency and decreases expired volume without altering AB phase durations. FASEB Journal 16(4): A67

Holton, R.A.; Tao, C. 2002: C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them. Official Gazette of the United States Patent and Trademark Office Patents 1254(3)

Holton, R.A.; Tao, C. 2003: C2 substituted taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1276(3)

Caforio, A.L.P.; Tona, F.; Piaserico, S.; Gambino, A.; Feltrin, G.; Fortina, A.B.; Angelini, A.; Peserico, A.; Thiene, G.; Iliceto, S.; Casarotto, D. 2003: C2 targets and multivariate predictors of C2 levels in stable heart transplant patients immunosuppressed on a C0-based regimen. Journal of Heart and Lung Transplantation 22(1S): S117

Billaud, E.M.; Antoine, C. 2002: C2 therapeutic drug monitoring of cyclosporine: sources of variability. Transplantation Proceedings 34(7): 2828-2830

Holton, R.A.; Tao, C. 2000: C2 tricyclic taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1231(4)

Fomina, O.L.; Petrovich, Y.A.; Volozhin, A.I.; Filatova, E.S. 2001: C2-C12 aldehydes, fatty acids, sulfur compounds in saliva and expired air during periodontitis and gingivitis. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S293

Han, D.S.; Kaplowitz, N. 2002: C2-ceramide and GD3-ganglioside Physiological regulators of superoxide generation in liver mitochondria. Hepatology 36(4 Part 2): 328A

Pregenzer, J.F.; Wilga, P.C.; Petrella, D.K.; Patel, R.K.; Mckim, J.M.J. 2003: C2-ceramide vs TNF-alpha induced cytotoxicity and apoptosis in a rat hepatoma cell line. Toxicological Sciences 72(S-1): 358

Einecke, G.; Mai, I.; Diekmann, F.; Fritsche, L.; Neumayer, H.H.; Budde, K. 2002: C2-levels of 600 ng/ml provide sufficient rejection prophylaxis in stable renal allograft recipients. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 371A

Jaehne, G.; Krone, V.; Bickel, M.; Gossel, M. 2004: C2-substituted idan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals. Official Gazette of the United States Patent and Trademark Office Patents 1284(2)

Jaehne, G.; Krone, V.; Bickel, M.; Gossel, M. 2003: C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals. Official Gazette of the United States Patent and Trademark Office Patents 1277(1)

Guipponi, Michel; Brunschwig, K.; Chamoun, Z.; Kudoh, Jun; Scott, H.S.; Al Samadi, S.; Delezoide, A.L.; Chettouh, Z.; Rossier, C.; Shimizu, N.; Mueller, F.; Delabar, J.M.; Antonarakis, S.E. 2000: C21orf5, a novel human chromosome 21 gene has a Celegans ortholog required for embryonic patterning. European Journal of Human Genetics 8(Suppl 1): 119-120

Nakata, E.; Raju, U.; Hunter, N.; Mason, K.; Fan, Z.; Ang, K.K.; Yamada, S.; Milas, L. 2003: C225 anti-EGFR antibody enhances the efficacy of docetaxel chemoradiotherapy. International Journal of Radiation Oncology Biology Physics 57(2 Suppl): S292-S293

Helfrich, B.; Raben, D.; Chan, D.; Garcia, L.; Shogun, T.; Zundel, W.; Hirsch, F.; Franklin, W.; Bunn, P. 2001: C225 anti-epidermal growth factor receptor monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo. International Journal of Radiation Oncology Biology Physics 51(3 Suppl 1): 187

Shimomura, H.; Furuta, H.; Tamai, M.; Hanabusa, T.; Nishi, M.; Nakao, T.; Sasaki, H.; Sanke, T.; Nanjo, K. 2002: C242T polymorphism of the NADP/NADPH oxidase p22 phox gene is associated with cardiovascular disease in Japanese type 2 diabetics. Diabetologia 45(Suppl 2): A 133-A 134

Moldowan, J.M.; Barbanti, S.M.; Fago, F.J.; Denisevich, P.; Dahl, J.; Trindade, L.A.F. 2003: C25 highly branched isoprenoid An age-related biomarker in oil. Abstracts of Papers American Chemical Society 225(1-2): GEOC 61

Fernandez, A.; Alonso, F.; Vega, N.; Hortal, L.; Baamonde, E.; Gallego, R.; Palop, L.; Garcia Laorden, J.; Manzanedo, A.; Dominguez, A.; Rodriguez Gallego, J.C. 2000: C282Y allele of the HFE gene and intravenous iron treatment in dialysis patients. Nephrology Dialysis Transplantation 15(9): A207

Wohllk, N.; Zapata, R.; Navarro, A.; Reyes, H. 2000: C282Y and H63D HFE gene mutations in patients with hemochromatosis and in healthy individuals, in Chile. Gastroenterology 118(4 Suppl 2 Pt 2): AASLD A149

Terra, C.; Dolinsky, L.C.; Coelho, H.S.M.; Segadas, J.; Vanderborght, B.O.M. 2000: C282Y and H63D hemochromatosis mutations prevalence in Brazilian HCV infected population. American Journal of Human Genetics 67(4 Suppl 2): 403

Tannapfel, A.; Stoelzel, U.; Koestler, E.; Melz, S.; Richter, M.; Keim, V.; Wittekind, C. 1999: C282Y and H63D mutation in the haemochromatosis gene in porphyria cutanea tarda in Germany. Gastroenterology 116(4 Part 2): A1282

Neid, M.; Tannapfel, A.; Wittekind, C. 2001: C282Y and H63D mutation of the hemochromatosis gene in patients with Non-Alcoholic Steatohepatitis. Pathology Research and Practice 197(5): 304

Girouard, J.; Giguere, Y.; Rousseau, F. 2001: C282Y and H63D mutations in the hemochromatosis gene Prevalence in neonates and at-risk individuals in the French-Canadian population. Clinical Chemistry 47(S6): A107

Spooner, R.J.; Jagger, C.E.; Halls, D.J.; Curry, G.; Thorburn, D.; Macsween, R.N.M.; Mills, P.R. 1999: C282Y heterozygosity of the HFE gene is not associated with altered iron status or increased fibrosis in chronic hepatitis C. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S152

Nilsson, A.K.; Persson, L.; Hietala, A.; Pekna, M. 1999: C3 and factor B deficient mice generated by gene targeting as a tool to study the role of the complement system in the pathogenesis of Alzheimers disease. Physiological Research 48(Suppl 1): S101

Nakamura, K.; Shin, D.H.; Dishaw, L.J.; Smith, S.L. 2003: C3 and factor I isoforms in the nurse shark, Ginglymostoma cirratum. FASEB Journal 17(7): C110

Smith, B.L.; Ferrieri, P. 2003: C3 binding polypeptide of Streptococcus agalactiae group b Streptococcus. Official Gazette of the United States Patent and Trademark Office Patents 1271(4)

Cunnion, K.M.; Lee, J.C.; Frank, M.M. 2000: C3 binding to S aureus. Clinical Infectious Diseases 31(1): 235

Davis, M.A. 2003: C3 grasses replace C4 grasses and reduce oak establishment in the prairie-forest border. Ecological Society of America Annual Meeting Abstracts 88: 82

Kocakova, P.; Drescher, K.M. 2004: C3 is required for efficient clearance of virus from the brains of TMEV-infected mice. FASEB Journal 18(4-5): Abstract 335

Askenazi, N.; Singer, N.G.; Gewurz, A.T. 2001: C3 nephritic factor in a child with fever and hypocomplementemia. Journal of Allergy and Clinical Immunology 107(2): S273

Chastain, C.J.; Sarath, G.; Chollet, R. 2001: C3 origins of the C4 pathway regulatory enzyme, PPDK-RP. Photosynthesis Research 69(1-3): 150

Mccarron, J.K.; Knapp, A.K. 2001: C3 shrub invasion in a C4 grassland Post-fire responses in resources and shoot growth. Ecological Society of America Annual Meeting Abstracts 86: 152

Posner, G.H.; Cumming, J.N.; Woo, S.H.ung 1999: C3 substituted trioxanes useful as antiparasitic drugs. Official Gazette of the United States Patent and Trademark Office Patents 1225(1)

Sheerin, N.S.; Springall, T.M.; Pratt, J.R.; Abe, K.; Sacks, S.H. 1999: C3 synthesis within the kidney The use of a transplantation protocol to determine function. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 537A

Cook, P.D.; An, H.; Wang, T.; Manoharan, M. 2002: C3-methylene hydrogen phosphonate monomers and related compounds. Official Gazette of the United States Patent and Trademark Office Patents 1260(1)

Cook, P.D.; Manoharan, M.; Maier, M.; An, H. 2003: C3-methylene hydrogen phosphonate oligomers and related compounds. Official Gazette of the United States Patent and Trademark Office Patents 1275(4)

Mitra, R.; Peters, M.W.; Scott, M.J. 2003: C3-symmetric ligand systems and their metal complexes as active site models of trinuclear metal sites in biology. Abstracts of Papers American Chemical Society 226(1-2): INOR 6

Scott, M.J.; Peters, M.W. 2002: C3-symmetric ligand systems and their metal complexes as enzyme active site models. Abstracts of Papers American Chemical Society 223(1-2): INOR 405

Sharrad, M.J.; Manning, N.J.; Heap, S.J.; Watkinson, J.M.; Allen, J.C.; Olpin, S.E.; Bonham, J.R. 2002: C3/C16 acyl carnitine ratio and methylcitrate excretion as alternatives in the monitoring of propionic acidaemia. Journal of Inherited Metabolic Disease 25(Suppl 1): 50

Angeloni, D.; Lee, J.D.; Johnson, B.E.; Teh, B.T.; Dean, M.; Lerman, M.I.; Sterneck, E. 2001: C306A single nucleotide polymorphism in the human CEBPD gene that maps at 8p11.1-p11.2. Molecular and Cellular Probes 15(6): 395-397

Seremak Mrozikiewicz, A.; Drews, K.; Semczuk, A.; Mrozikiewicz, P.M. 2003: C3435T polymorphism of the MDR1 gene is correlated with endometrial cancer. Tulunay, F C, Orme, M European collaboration: Towards drug development and rational drug therapy: 174

Sahasrabudhe, D.M.; Evans, E.E.; Borrello, M.; Belanger, T.; Henn, A.; Paris, M.; Smith, E.; Zauderer, M. 2002: C35 A novel immunotherapy target in breast cancer. International Journal of Cancer Suppl (13): 88

Evans, E.E.; Borrello, M.; Belanger, T.; Henn, A.; Paris, M.; Luhowskyj, S.; Smith, E.S.; Sahasrabudhe, D.M.; Zauderer, M. 2001: C35 is a novel immunotherapy target expressed in human breast and bladder carcinoma. Breast Cancer Research and Treatment 69(3): 311

Wang Zejun; Qi Changqing; Chen Wengjun; Hu Jilan; An Xuxiang; Zhang Chunying 1999: C3905 A, an antitumor antibiotics from rare actinomycete in Antarctica, isolation, properties and identification. Zhongguo Kangshengsu Zazhi 24(5): 388-391

Werner, J.; Herfarth, C.; Klar, E. 2000: C3A and leukocyte counts, but not endotoxin, endotoxin-neutralizing capacity, C-reactive protein or procalcitonin predict survival in patients with severe peritonitis. Gastroenterology 118(4 Suppl 2 Pt 2): SSAT A1536

Lee, D.; Bondinell, W.E.; Jurewicz, A.J. 2002: C3A receptor ligands. Official Gazette of the United States Patent and Trademark Office Patents 1265(1)

Grimsditch, D.C.; Penfold, S.; Latcham, J.; Vidgeon-Hart, M.; Groot, P.H.; Benson, G.M. 2000: C3H apoE(-/-) mice have less atherosclerosis than C57BL apoE(-/-) mice despite having a more atherogenic serum lipid profile. Atherosclerosis 151(2): 389-397

Igolnikov, A.C.; Spatz, K.; Green, R.M. 2002: C3H/HeJ mice with mutations of the Toll-like receptor 4 are resistant to methionine-choline deficient diet induced non-alcoholic steatohepatitis. Hepatology 36(4 Part 2): 404A

Jelezarova, E.; Lutz, H.U.; Schlumberger, M.; Sadallah, S.; Trendelenburg, M.; Kirschfink, M.; Lopez Trascasa, M.; Spath, P.J.; Schifferli, J.A. 2001: C3NeF determined by a solid phase immunoassay in patients with membranoproliferative glomerulonephritis , systemic lupus erythematosus and post streptococcal nephritis. Molecular Immunology 38(2-3): 99-100

Jauneau, A.C.; Ischenko, A.; Chan, P.; Patte, C.; Chatagner, A.; Vaudry, H.; Fontaine, M. 2001: C3a and C5a anaphylatoxins induce upregulation of neurotrophin expression by astrocytes. Molecular Immunology 38(2-3): 98

Honczarenko, M.; Swierkowski, M.; Le, Y.; Glodek, A.M.; Ratajczak, M.Z.; Nicholson Weller, A.; Silberstein, L.E. 2003: C3a primes B cell responses to SDF-1/CXCL12 by increasing its binding affinity to the CXCR4 chemokine receptor. Blood 102(11): 823a

Hawlisch, H.; Mueller, M.; Frank, R.; Bautsch, W.; Klos, A.; Koehl, J. 2000: C3a receptor-specific single chain antibodies derived by a differential panning procedure on cellulose sheets. Immunobiology 203(1-2): 441

Humbles, A.A.; Lu, B.; Gerard, N.P.; Gerard, C. 2000: C3aR A central mediator of allergic asthma. Immunopharmacology 49(1-2): 80

Welcher, A.A.; Elliott, G.S. 2003: C3b/C4b complement receptor-like molecules and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1277(1)

Brown,N.J.; Palmer,B.G.; Stanley,S.; Hajaji,H.; Janacek,S.H.; Astley,H.M.; Parsley,K.; Kajala,K.; Quick,W.P.; Trenkamp,S.; Fernie,A.R.; Maurino,V.G.; Hibberd,J.M. 2010: C4 acid decarboxylases required for C4 photosynthesis are active in the mid-vein of the C3 species Arabidopsis thaliana, and are important in sugar and amino acid metabolism. Plant Journal: 1, 122-133

Grumach, A.S.; Rutz, R.; Kirschfink, M. 2001: C4 allotypes in IgA deficient patients. Molecular Immunology 38(2-3): 94-95

Inal, J.M.; Schifferli, J.A. 2001: C4 beta chain peptide interferes with the formation of the classical pathway C2 convertase. Molecular Immunology 38(2-3): 97

Azofra, J.; López-Trascasa, M. 2001: C4 deficiency in chronic angioedema. Allergy 56(11): 1106-1107

Paul, E.; Carroll, M.C. 2002: C4 deficiency modulates negative selection of autoreactive B cells. International Immunopharmacology 2(9): 1352-1353

Soubra, S.H.; Vernarske, D.; Bag, R.; Frost, A.E. 2002: C4 levels of tacrolimus correlate best with area under the curve in pancreatic insufficient cystic fibrosis patients. Journal of Heart and Lung Transplantation 21(1): 85

Furbank, R.T.; Hatch, M.D.; Jenkins, C.L.D. 2000: C4 photosynthesis Mechanism and regulation. Leegood, Richard C , Reprint Author, Sharkey, Thomas D, von Caemmerer, Susanne, Kennedy, Robert Photosynthesis: Physiology and metabolism: 435-457

Long, Stephen P.; Al Shoaibi, Abdul K.; Beale, Clive V.; Farage, Peter K.; Baker, Neil R. 1999: C4 photosynthesis has gone into the cold. Plant Biology (Rockville) : 117

Cuccia, M.; De Silvestri, A.; Martinetti, M.; Tinelli, C.; Belloni, C.; Salvaneschi, L. 1999: C4 polymorphisms and role of C4AQ0 in humoral response to differing vaccines A multivariate analysis of HLA genes. Molecular Immunology 36(4-5): 287

Pozdnyakova, O.O.; Paul, E.; Schneider, T.J.; Carroll, M.C. 2000: C4- and CD21/CD35-deficiency predisposes mice to spontaneous autoreactivity. Immunopharmacology 49(1-2): 79

Pfitzenmaier, J.; Quinn, J.E.; Odman, A.; Zhang, J.; Keller, E.T.; Vessella, R.L.; Corey, E. 2003: C4-2 tibial injection An animal model for examination of prostate cancer bone metastases and its response to castration. Journal of Urology 169(4 Suppl): 212

Traustadottir, K.H.; Sigfusson, A.; Steinsson, K.; Erlendsson, K. 2001: C4A deficient individuals may beat increased risk of systemic lupus erythematosus due to diminished reserve to deposit C3b on immune complexes when exposed to increased immune complex load. Journal of Allergy and Clinical Immunology 107(2): S275

Hoehler, T.; Stradmaann Bellinghausen, B.; Starke, R.; Sanger, R.; Victor, A.; Rittner, C.; Schneider, P. 2002: C4A dificiencies show a strong independent association with HBsAG vaccination failure. Journal of Hepatology 36(Suppl 1): 8

Gadjeva, M.; Carroll, M. 2000: C4A-like and C4B-like animal models. Immunopharmacology 49(1-2): 12

Myones, B.L.; Shulman, S.T.; Moulds, J.M. 2002: C4A/C4B polymorphisms in Kawasaki Disease. International Immunopharmacology 2(9): 1387

Man, X.Y.; Luo, H.R.; Li, X.P.; Yao, Y.G.; Mao, C.Z.; Zhang, Y.P. 2001: C4AQ0 and C4BQ0 genotyping Association with systemic lupus erythematosus. American Journal of Human Genetics 69(4 Suppl): 566

Lahti, M.; Jaatinen, T.; Ruuskanen, O.; Truedsson, L.; Lokki, M.L. 1999: C4B deficiency due to gene deletions and gene conversion in severe infections. Molecular Immunology 36(4-5): 290

Kristjansdottir, H.; Johannsdottir, K.; Steinsson, K.; Erlendsson, K. 2003: C4a deficiency and complement-mediated binding of immune complexes in Icelandic muticase SLE families Correlation to SLE disease criteria. Molecular Immunology 40(2-4): 214

Accardo, P.; Amodeo, G.; Bergamaschini, L.; Cicardi, M.; Agostoni, A.; Brai, M. 1999: C4b overloading of C4BP in hereditary angioedema. Molecular Immunology 36(4-5): 277

Sim, D.S.; Thiel, S.; Devine, D.V. 2000: C4b-binding protein and mannose binding lectin interactions with beta2-glycoprotein I Association of complement activation and antiphospholipid antibodies. Immunopharmacology 49(1-2): 83

Angelini, F.; Bacharier, L.; Fujiwara, H.; Brodeur, S.R.; Blom, A.M.; Dahlback, B.; Tsitsikov, E.; Geha, R.S. 2001: C4b-binding protein binds CD40 and modulates CD40 signaling. Journal of Allergy and Clinical Immunology 107(2): S137

Ram, S.; Boden, R.; Stein, D.C.; Cox, A.D.; O'reilly, B.; Apicella, M.A.; Gulati, S.; Blom, A.M.; Rice, P.A. 2002: C4b-binding protein interactions with Neisseria gonorrhoeae porin is influenced by hexose substitutions on the heptose I chain of lipooligosaccharide. International Immunopharmacology 2(9): 1336-1337

Arnaiz Villena, A.; Martinez Quiles, N.; Paz Artal, E.; Moreno Pelayo, M.A.; Longas, J.; Ferre Lopez, S.; Rosal, M.; Varela, P.; Morales, P.; Moreno, D.; Rubio, I.; Martinez Laso, J. 1999: C4d DNA sequences of two infrequent human allotypes and the presence of signal sequences enhancing recombination. Human Immunology 60(Suppl 1): S38

Pope Harman, A.; Ross, P.; Magro, C.; Kelsey, M. 2003: C4d as a diagnostic adjunct in lung allograft biopsies. Journal of Heart and Lung Transplantation 22(1S): S103

Roy Chaudhury, P.; Armstrong, J.; Mckee, L.; Zhang, J.; Govil, A.; Peddi, R.; Woodle, S.; First, R.; Heffelfinger, S.; Mutema, G.; Smith, R.; Cavallo, T. 2002: C4d deposition in chronic allograft dysfunction. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 558A

Nickerson, P.; Gibson, I.; Karpinski, M.; Regele, H.; Exner, M.; Jeffery, J.; Rush, D. 2002: C4d deposition in protocol biopsies from flow-cytometry crossmatch positive or renal transplant recipients. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 567A-568A

Regele, H.; Exner, M.; Watschinger, B.; Wenter, C.; Wahrmann, M.; Osterreicher, C.; Saemann, M.D.; Mersich, N.; Horl, W.H.; Zlabinger, G.J.; Bohmig, G.A. 2000: C4d deposition in renal allografts predicts inferior graft outcome independently of cellular rejection. Kidney and Blood Pressure Research 23(3-5): 330

Fiebeler, A.; Mengel, M.; Merkel, S.; Mushoff, U.; Klos, A.; Gwinner, W.; Haller, H.; Schwarz, A. 2002: C4d deposition is increased in subclinical humoral rejection of renal allografts. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 568A

Mauiyyedi, S.; Della Pelle, P.; Saidman, S.; Collins, A.B.; Pascual, M.; Tolkoff Rubin, N.; Schneeberger, E.; Colvin, R.B. 1999: C4d deposits in peritubular capillaries in chronic renal allograft rejection. Modern Pathology 12(1): 156A

Böhmig, G.A.; Exner, M.; Watschinger, B.; Wenter, C.; Wahrmann, M.; Osterreicher, C.; Säemann, M.D.; Mersich, N.; Hörl, W.H.; Zlabinger, G.J.; Regele, H. 2001: C4d deposits in renal allografts are associated with inferior graft outcome. Transplantation Proceedings 33(1-2): 1151-1152

Campbell, P.M.; Jhangri, G.S.; Gourishankar, S.; Cockfield, S.M.; Solez, K.; Halloran, P.F. 2001: C4d staining in late graft dysfunction is related to late acute rejection rather than chronic rejection. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 880A

Smith, R.N.; Brousaides, N.; Saidman, S.; Collins, A.B. 2004: C4d staining of cardiac allografts correlates with alloantibody. Journal of Heart and Lung Transplantation 23(2S): S122

Haas, M.; Ratner, L.E.; Montgomery, R.A. 2002: C4d staining of perioperative renal transplant biopsies. Transplantation 74(5): 711-717

Habicht, A.; Regele, H.; Exner, M.; Soleiman, A.; Druml, W.; Derfler, K.; Kovarik, J.; Hoerl, W.H.; Watschinger, B.; Boehmig, G.A. 2001: C4d-positive acute humoral renal allograft rejection in spousal-donor kidney transplantation. Kidney and Blood Pressure Research 24(4-6): 274-275

Nussmeier, N.A.; Fitch, J.C.K.; Malloy, K.J.; Shernan, S.K. 2001: C5-complement suppression by pexelizumab in CABG patients is associated with reduction of postoperative myocardial infarction. Circulation 104(17): 2; 150

Rauch, C.; Trieb, M.; Wellenzohn, B.; Loferer, M.; Voegele, A.; Wibowo, F.R.; Liedl, K.R. 2003: C5-methylation of cytosine in B-DNA thermodynamically and kinetically stabilizes Bi. Journal of the American Chemical Society 125(49): 14990-14991

Evans, M.J.; Matis, L.A.; Mueller, E.E.; Nye, S.H.; Rollins, S.; Rother, R.P.; Springhorn, J.P.; Squinto, S.P.; Thomas, T.C.; Wilkins, J.A. 2002: C5-specific antibodies for the treatment of inflammatory diseases. Official Gazette of the United States Patent and Trademark Office Patents 1256(2)

Sacconi, S.; Salviati, L.; Nishigaki, Y.; Pons, R.; Devivo, D.C.; Shanske, S.; Bonilla, E.; Davidson, M.; Dimauro, S. 2002: C5545T A dominant mitochondrial DNA mutation?. Neurology 58(7 Suppl 3): A330

Davidson, M.; Sacconi, S.; Salviati, L.; Hernandez, E.; Nishigaki, Y.; Pons, R.; Devivo, D.; Shanske, S.; Schon, E.A.; Bonilla, E.; Dimauro, S. 2003: C5545T A novel functionally dominant mitochondrial DNA mutation. American Journal of Human Genetics 73(5): 349

Atochina, E.N.; Haczku, A.; Tomer, Y.; Chen, H.; Scanlon, S.T.; Russo, S.; Panettieri, R.A.; Beers, M.F. 2002: C57/BL-6 mice produce higher levels of surfactant protein -D and attenuated airway responses in comparison with Balb/c mice following allergic sensitization. Journal of Allergy and Clinical Immunology 109(1 Suppl): S23

Titus, R.G.; Dekrey, G.K.; Mbow, M.L.; Brodskyn, C.I. 1999: C57B1/6 B cell knockout mice resist infection with Leishmania major. FASEB Journal 13(4 Part 1): A636

Gabr, U.; Sung, Y.; Baroody, F.M.; Naclerio, R.M. 2000: C57B1/6 and BALB/c mice respond similarly to Streptococcus pneumonia infection of the paranasal sinuses. Journal of Allergy and Clinical Immunology 105(1 part 2): S212

Haczku, A.; Mclane, M.P.; Rani, U.P.; Weiss, C.; Ferrante, V.; Tomer, Y.; Nixon, N.N.; Holroyd, K.J.; Nicolaides, N.C.; Levitt, R.C. 1999: C57BL/6 mice are impaired in antigen induced IgE and IgC1 production in vitro. Journal of Allergy and Clinical Immunology 103(1 Part 2): S87

Haluzik, M.; Colombo, C.; Cutson, J.; Dietz, K.R.; Gavrilova, O.; Reitman, M.L. 2002: C57BL/6J vs FVB/N genetic background strongly influences liver and muscle insulin sensitivity in lipoatrophic A-ZIP/F-1 mice. Diabetologia 45(Suppl 2): A 83

Wotjak, C.T. 2003: C57BLack/BOX? the importance of exact mouse strain nomenclature. Trends in Genetics: Tig 19(4): 183-184

Dekrey, G.K.; Mbow, M.L.; Brodskyn, C.I.; Titus, R.G. 2000: C57Bl/6 B cell deficient mice resist secondary infection with Leishmania major but with greatly reduced inflammation. FASEB Journal 14(6): A953

Von Stebut, E.; Udey, M.C. 2000: C57b1/6 and BALB/c skin-derived dendritic cells produce different amounts of IL-1alpha DC-derived IL-1alpha may antagonize Th2 development in mice that are genetically resistant to Leishmania major. Journal of Investigative Dermatology 114(1): 212 A

Zetoune, F.S.; Mcguire, S.; Sarma, J.V.; Rittirsch, D.; Huber Lang, M.; Ward, P.A. 2004: C5L2 express in rat neutrophils during sepsis. FASEB Journal 18(4-5): Abstract 777

Zetoune, F.S.; Ward, P.A.; Guo, R.F.; Neff, T.A.; Sarma, V.; Younkin, E.M.; Riedemann, N.C. 2002: C5a as a probe for understanding the complications in experimental sepsis. International Immunopharmacology 2(9): 1361

Trujillo, G.; Kew, R.R. 2003: C5a chemotactic cofactor function of the vitamin D binding protein Insight into the cellular mechanism using U937 cells transfected with the C5a receptor. Journal of Leukocyte Biology Suppl: 29

Perianayagam, M.C.; Balakrishnan, V.S.; Pereira, B.J.G.; Jaber, B.L. 2003: C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and bad-mediated signaling pathway. Journal of the American Society of Nephrology 14(Abstracts Issue): 344A

Perianayagam, M.C.; Balakrishnan, V.S.; Pereira, B.J.G.; Jaber, B.L. 2002: C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase signaling pathway. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 292A-293A

Huber Lang, M.; Younkin, E.; Mcguire, S.R.; Lu, K.; Sarma, V.; Ward, P.A. 2000: C5a generation by alveolar macrophages. Immunopharmacology 49(1-2): 47

Heinrich, A.; Schulze, L.; Zwirner, J.; Rieber, P.; Schaekel, K. 2004: C5a modulates phenotype, cytokine production and T cell programming of M-DC8+ human blood dendritic cells. Archives of Dermatological Research 295(8-9): 352

Pellas, T.C.; Wennogle, L.P. 1999: C5a receptor antagonists. Current Pharmaceutical Design 5(10): 737-755

Laudes, I.J.; Huber Lang, M.; Speyer, C.; Albrecht, E.; Chu, J.; Murphy, H.; Riedemann, N.; Sarma, V.; Ward, P.A. 2001: C5a receptor expression on rat endothelial cells. FASEB Journal 15(5): A1183

Hawlisch, H.; Heller, T.; Tschernig, T.; Klos, A.; Koehl, J. 2002: C5a triggers the contact hypersensitivity in mice and is a potential therapeutic target. International Immunopharmacology 2(9): 1371

Chronopoulou, E.; Ember, J.A.; Song, S.; Dong, L.P.; Ji, X.D.; Wang, X.D.; Zou, J.C.; Shi, L.; Stall, A.; Sanderson, S.D.; Shih, C.C.Y.; Morgan, E. 2000: C5a- and C3a-receptors detected with high affinity monoclonals of rabbit and mouse origin. Immunopharmacology 49(1-2): 89

Zwirner, J.; Soruri, A. 2000: C5a-induced differentiation of human monocytes into dendritic cells in a SCID mouse model. Immunobiology 203(1-2): 396

Huber Lang, M.S.; Sarma, J.V.; Younkin, E.M.; Guo, R.F.; Mcguire, S.R.; Lu, K.T.; Gebhard, F.; Ward, P.A. 2002: C5a-induced impairment of innate immunity during experimental sepsis. FASEB Journal 16(4): A592

Sanderson, S.; Reinhardt, R.; Jackson, J. 2000: C5a-mediated release of IL-6 from C5a receptor-bearing human osteoblasts. Immunopharmacology 49(1-2): 96

Tyagi, S.; Klickstein, L.B.; Nicholson Weller, A. 2000: C5a-stimulated human neutrophils utilize CR3, but not LFA-1 to supports the adhesion -dependent phase of superoxide production. Immunopharmacology 49(1-2): 4

Huber Lang, M.; Sarma, V.; Riedemann, N.; Laudes, I.; Younkin, E.; Mcguire, S.; Lu, K.; Guo, R.; Albrecht, E.; Lambrics, J.; Ward, P.A. 2001: C5aR antagonist is protective in experimental sepsis in mice. FASEB Journal 15(5): A1183

Rus, H.; Jansen, T.; Cudrici, C.; Niculescu, T.; Reed, J.; Fosbrink, M.; Niculescu, F.I. 2004: C5b-9 Terminal Complement Complex Protects Oligodendrocytes from apoptosis by regulating FLIP. FASEB Journal 18(4-5): Abstract 777

Soane, L.; Niculescu, F.; Rus, H.; Shin, M.L. 2001: C5b-9 complement complex protects oligodendrocytes from apoptosis by regulating BAD and BCL-2 through phosphatidylinositol 3-kinase/AKT and ERK pathways. Molecular Immunology 38(2-3): 122-123

Rus, H.; Badea, T.; Soane, L.; Fosbrink, M.; Hila, S.; Rus, V.; Shin, M.L.; Niculescu, F.I. 2002: C5b-9 induced RGC-32 increases cdc2 kinase activity and activate cell cycle. FASEB Journal 16(4): A681

Pippin, J.W.; Couser, W.G.; Shankland, S.J. 1999: C5b-9 induces and augments mesangial cell proliferation in vitro and in vivo. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 518A-519A

Rangan, G.K.; Pippin, J.; Takeuchi, Y.; Couser, W.G. 2000: C5b-9 mediates cortical interstitial disease and tubular expression of RelA in proteinuric rats. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 515A

Kovaru, F.; Kovaru, H.; Fiserova, A.; Matalova, E.; Palikova, M.; Ivan, M. 2003: C6 glioma cells as targets in recognition events of natural killer cytotoxicity. Neuroimmunomodulation 10(1): 69, August, 2002-

Suzuki, M.; Suzuki, M.; Nakayama, J.; Fukuda, M. 2003: C6 glioma invasion into corpus callosum is facilitated by polysialylation of NCAM. Glycobiology 13(11): 903

Nangaku, M.; Pippin, J.; Couser, W.G. 2001: C6 mediates chronic progressive renal disease in remnant kidney rats. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 688A

Ocampo, M.A.; Del Angel, R.M. 2000: C6/36 cell proteins bind to the steam-loop structure into the 3untranslated region from dengue 4 virus. American Journal of Tropical Medicine and Hygiene 62(3 Suppl): 346

Caserman, S.; Gorinsek, B.; Bergant, D.; Ravnik Glavac, M.; Glavac, D. 1999: C618R mutation in the RET proto-oncogene in a Slovenian kindred with a medulary thyroid carcinoma and Hirschprung disease. European Journal of Human Genetics 7(Suppl 1): 53

Shcherbak, N.; Shutskaya, Z.; Sheydina, A.; Stroykova, A.; Schwartz, E. 1999: C677T MTHFR mutation as independent risk factor of diabetic nephropathy in IDDM. European Journal of Human Genetics 7(Suppl 1): 147

Mougiou, A.; Symeonidis, A.; Karakantza, M.; Sakellaropoulos, G.; Zoumbos, N.C.; Maniatis, A.G. 2002: C677T Polymorphism in 5,10-Methylenetetrahydrofolate Reductase Gene Is Not Associated with a Protective Effect for Myelodysplastic Syndromes and Chronic Lymphoproliferative Disorders. Blood 100(11): Abstract No. 4312

Giusti, B.; Padeletti, L.; Marcucci, R.; Betti, I.; Lucarini, L.; Evangelisti, L.; Prisco, D.; Gensini, G. 2003: C677T and A1298C methylene-tetrahydrofolate reductase gene polymorphisms in atrial fibrillation. European Heart Journal 24(Abstract Suppl): 42

Soon, S.Y.; Ansari, A.; Hernandez, M.; Marinaki, T.; Sanderson, J.D. 2004: C677T and A1298C methylenetetrahydrofolate reductase gene polymorphism does not predict toxicity or efficacy of methotrexate in patients with inflammatory bowel disease. Gut 53(Suppl 3): A104-A105

Bik Multanowski, M.; Pietryzk, J.J.; Sanak, M.; Czachor, R. 2000: C677T and A1298C mutations of the 5,10-methylenetetrahydrofolate reductase gene as a risk factor for neural tube defects in Polishpopulation Preliminary study. European Journal of Human Genetics 8(Suppl 1): 137

Al-Habboubi, H.; Tamim, H.; Ameen, G.; Almawi, W.Y. 2004: C677T and A1298C single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene among Bahraini Arabs. Thrombosis and Haemostasis 91(4): 843-845

Elstein, E.; Huan, C.; Fitchett, D.; Cantarovitch, M.; Marpole, D. 1999: C677T gene mutation in methylenetetrahydrofolate reductase as a risk factor for cardiac allograft vasculopathy. Transplantation Proceedings 31(1-2): 99

Levy, P.J.; Yunis, C.; Owen, J.; Ferrario, C.M. 2000: C677T methylenehydrofolate reductase and Factor V Leiden mutations in patients with premature lower extremity atherosclerosis are associated with systemic cardiovascular disease. Journal of the American College of Cardiology 35(2 Suppl A): 283A

Zuniga Noriega, J.R.; Velazco Campos, M.D.R.; Aguirre Rodriguez, A.; Tijerina Menchaca, R.; Ancer Rodriguez, J.; Maldonado Garza, H.; Garza Gonzalez, E.; Martinez, D.V.llarreal, L.; Bosques Padilla, F.J. 2003: C677T polymorphism of methylene-tetrahydrofolate reductase and the risk to develop gastric cancer in a population of Mexico. IJMM International Journal of Medical Microbiology 293(Suppl 35): 123

Zuniga Noriega, J.R.; Velazco Campos, M.R.; Aguirre Rodriguez, A.A.; Tijerina Menchaca, R.; Ancer Rodriguez, J.; Maldonado Garza, H.J.; Garza Gonzalez, E.; Martinez, D.V.llarreal, L.E.; Bosques Padilla, F.J. 2003: C677T polymorphism of the 5, 10 methylene-tetrahydrofolate reductase and the risk to develop gastric cancer in a population of Mexico. Helicobacter 8(4): 423

Holton, R.A.; Chai, K.B.ung 2002: C7 acyloxy and hydrido taxane derivatives and pharmaceutical compositions containing them. Official Gazette of the United States Patent and Trademark Office Patents 1263(2)

Holton, R.A.; Chai, K.B.ung 2004: C7 acyloxy metal alkoxides. Official Gazette of the United States Patent and Trademark Office Patents 1284(2)

Holton, R.A. 2004: C7 carbamate substituted taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1283(3)

Holton, R.A. 2002: C7 carbamoyloxy substituted taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1256(3)

Holton, R.A. 2004: C7 carbonate substituted taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1285(4)

Holton, R.A. 2003: C7 ester substituted taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1273(4)

Holton, R.A. 2004: C7 heterosubstituted acetate taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1278(1)

Holton, R.A.; Chai, K.B.ung 1999: C7 tricyclic taxanes. Official Gazette of the United States Patent and Trademark Office Patents 1228(5)

Horikoshi, T.; Endo, N.; Shibata, M.; Suzuki, M.; Takahashi, E.; Shinka, T.; Nakahori, Y.; Ayusawa, D.; Nakabayashi, K.; Scherer, S.W.; Noji, S. 2001: C7orf2 gene is interrupted within intronic region by a de novo reciprocal chromosomal translocation t in a patient with preaxial polydactyly. American Journal of Human Genetics 69(4 Suppl): 610

Beaudoin, A.R.; Gendron, F.P.; Halbfinger, E.; Fischer, B. 2003: C8-substituted purine nucleotide analogs. Official Gazette of the United States Patent and Trademark Office Patents 1274(2)

Von Beckerath, N.; Koch, W.; Kastrati, A.; Seyfarth, M.; Fessel, C.; Schoemig, A. 1999: C825T polymorphism in the gene encoding for the beta3 subunit of heterotrimeric G proteins is not associated with an increased risk of thrombosis and restenosis following coronary stent placement. European Heart Journal 20(ABSTR Suppl ): 531

Zeltner, R.; Delles, C.; Schneider, M.; Siffert, W.; Schmieder, R. 2000: C825T polymorphism of the G protein beta3 subunit gene is associated with enhanced renal plasma flow. Journal of Hypertension 18(Suppl 4): S185

Petershofen, E.K.; Gross, J.; Pindur, G.; Witt, I.; Wenzel, E.; Seifried, E. 1999: C8571A A novel heterozygotic point mutation in the protein C gene. Annals of Hematology 78(Suppl 1): A86

Holton, R.A.; Chai, K.B.; Suzuki, Y. 2004: C9 hydrido and acyloxy metal alkoxides. Official Gazette of the United States Patent and Trademark Office Patents 1286(4)

Holton, R.A.; Chai, K.B.; Suzuki, Y. 2002: C9 hydrido, hydroxy and acyloxy taxane derivatives and pharmaceutical compositions containing them. Official Gazette of the United States Patent and Trademark Office Patents 1264(3)

Holton, R.A.; Somoza, C.; Suzuki, Y.; Shindo, M. 2000: C9 taxane derivatives. Official Gazette of the United States Patent and Trademark Office Patents 1240(2)

Holton, R.A.; Chai, K.B.; Suzuki, Y. 2000: C9 taxane derivatives and pharmaceutical compositions containing them. Official Gazette of the United States Patent and Trademark Office Patents 1230(1)

Lee, K.S.; Lee, W.Y. 2000: CA -ATPase in aged erythrocyte. Cell Biology International 24(12): 961-962

Naegele, H.; Bahlo, M.; Bohlman, M.; Dapper, F.; Klapdor, R.; Roediger, W. 1999: CA 12-5 A prognostic marker in heart failure?. European Heart Journal 20(ABSTR Suppl ): 258

Verheijen, R.H.; von Mensdorff-Pouilly, S.; van Kamp, G.J.; Kenemans, P. 1999: CA 125: fundamental and clinical aspects. Seminars in Cancer Biology 9(2): 117-124

Van Dalen, A.; Favier, J.; Baumgarten, L.; Haeholzner, U.; De Bruijn, H.; Dombi, V.H.; Fink, D.; Dobler, D.; Giai, M.; Mcging, P.; Harlozinska, A.; Kainz, Ch; Markowska, J.; Molina, R.; Sturgeon, C.; Einarsson, R. 1999: CA 125 and TPS for the prediction of therapeutic response in ovarian cancer. Anticancer Research 19(6D): 5692

Chang, A.Y.; Stein, J.P.; Groshen, S.; Skinner, D.G. 2002: CA 125 as a preoperative prognostic marker in transitional cell carcinoma of the bladder. Journal of Urology 167(4 Suppl): 308

Fusshoeller, A.; Grabensee, B.; Plum, J. 1999: CA 125 in the effluent of chronic PD patients Relation to PD duration, peritonitis and peritoneal transport. Kidney and Blood Pressure Research 22(4-6): 350-351

Carcenac, G.; Georges, A.; Bordenave, L. 2004: CA 125 kinetic pattern during chemotherapy. Annales de Biologie Clinique 62(1): 99-102

Duffy, M.J.; Shering, S.G.; Sherry, F.; Mc Dermott, E.; O'higgins, N. 1999: CA 15-3 A circulating prognostic marker in breast cancer. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S224

Lauro, S.; Lanzetta, G.; Trasatti, L.; Bordin, F.; Bria, E.; Reale, M.G.; Frati, L. 1999: CA 15-3 and CA 27-29 serum markers in monitoring breast cancer patients. European Journal of Cancer 35(Suppl 4): S116

Duffy, M.J. 1999: CA 15-3 and related mucins as circulating markers in breast cancer. Annals of Clinical Biochemistry 36: 579-586

Klapdor, R.; Bahlo, M.; Fenner, C. 1999: CA 19-9 Indications and preconditions for routine use in pancreatic cancer disease. Anticancer Research 19(6D): 5681

Kirk, K.; Kasmin, F.E.; Cohen, S.A.; Siegel, J.H. 2001: CA 19-9 as a predictor of cancer in the presence of pancreatic stricture demonstrated by ERCP. Gastroenterology 120(5 Suppl 1): A 609

Klapdor, R.; Bahle, M.; Babinsky, M. 2003: CA 19-9 in the follow-up of pancreatic cancer. Anticancer Research 23(6B): 4487

Khanna, A.K.; Yadav, S.K.; Dixit, V.K.; Nath, G.; Kumar, M.; Khanna, A. 2004: CA 19-9 in various gastrointestinal malignancies in an Indian population. Tropical Doctor 34(2): 107-108

Gruson, D.; Philippe, M.; De Nayer, P. 2004: CA 199 assay From RIA to non-radioisotopic automated methods, a clinical report of cut-off disagreement cases. Clinical Chemistry 50(6, Suppl S, Part 2): A72

Duc Van, D.; Hanh Phuc, H.; Kim Chi, D.; Qioc Bihn, N.; Sinh Hien, N.; Thu Ha, H.; Van Son, H. 1999: CA 72-4 in the diagnosis and the monitoring of gastric cancer. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S241

Santibanez, M.F.; Gangeswaran, R.; Hancock, J.M. 1999: CA repeat stimulated recombination The role of mismatch repair in an E coli model. American Journal of Human Genetics 65(4): A320

Krumina, A.; Krumina, L.; Lazdins, M.; Svabe, V.; Krumina, Z.; Teibe, U.; Baumanis, V. 2002: CA repeats in the first intron of the CFTR gene in cystic fibrosis patients and healthy Latvians. European Journal of Human Genetics 10(Suppl 1): 213

Schroeter, M.M.; Chalovich, J.M.chael 2004: CA++-calmodulin regulates actin polymerisation by fesselin. Biophysical Journal 86(1): 67a

Roberts, L.D.; Valencia, T.; Zeng, H.; Grant, S. 2000: CA+2/calmodulin-dependent protein kinase-IIalpha negatively regulates the induction of hypertrophic response initiated by Ca+2 dependent protein kinases and phosphatases. Journal of Investigative Medicine 48(1): 160A

Miralles, C.; Orea, M.; Sanchez, A.; Cantos, B.; Gea, T.; Cubedo, R.; Bonilla, F.; Espana, P. 2001: CA-125 Associated with benign and malignant pathologies. European Journal of Cancer 37(Suppl 6): S240

Dyer, M.W.; Callum, M.G.; Izes, J.K.; Mccaffrey, J.A.; Libertino, J.A. 2000: CA-125 Long-term results as a tumor marker for bladder cancer. Journal of Urology 163(4 Suppl): 235

Dursun, P.; Basaran, M.; Yüce, K. 2003: CA-125 elevation in malignant and nonmalignant conditions. European Journal of Gynaecological Oncology 24(6): 584; author reply 585

Mcdonnel, A.C.; Van Kirk, E.A.; Austin, K.J.; Hansen, T.R.; Belden, E.L.; Murdoch, W.J. 2003: CA-125 expression by progestational bovine endometrium Prospective regulation and function. Biology of Reproduction 68(Suppl 1): 263-264

Jelic, S.; Filipovic Ljeskovic, I.; Tasic, S.; Ristic, D. 2003: CA-125 in malignant lymphoma, is it a reliable parameter for disease monitoring? Discordant results of two assays involving monoclonal antibodies. Leukemia 17(3): 673

Branco, P.; Carrilho, P.; Mendes, A.; Gaspar, A.; Marques, F. 2000: CA-125 in peritoneal dialysis. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 316A

Firth, G.; Frowen, C.; Metcalfe, J. 2001: CA-125 levels in patients with congestive cardiac failure. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S169

Kaneko, S.; Young, S.R.; Gerasimova, T.; Smith, S.T.; Lloyd, K.O. 2002: CA125 FISH studies of ovarian carcinoma. Cytogenetic and Genome Research 97(3-4): 274

Gotlieb, W.H.; Soriano, D.; Flikker, S.; Achiron, R.; Baruch, G.B.n 1999: CA125 and ultrasound in borderline tumors of the ovary. Gynecologic Oncology 72(3): 484

Beaudin, J.; Boivin, M.; Migneault, M.; Piche, A.; Rancourt, C. 2003: CA125 cell surface down-regulation mediated by intracellular single-chain antibodies results in an increased cell proliferation and decreased cell-cell interactions. Proceedings of the American Association for Cancer Research 44: 813

Sanusi, A.A.; Zweers, M.M.; Mateijsen, M.A.M.; Weening, J.J.; Struijk, D.G.; Krediet, R.T. 1999: CA125 in effluent mesothelial cells during peritoneal dialysis. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 229A

Nustad, K.; Olsen, K.H.; O'brien, T.J.; Beard, J.; Warren, D.J. 2003: CA125 repeat 1 Expression, purification and characterization of epitopes for CA125 antibodies. Tumor Biology 24(Suppl 1): 32

Smyth, J.F.; Bowman, A.; Gabra, H.; Lessels, A.; Stewart, M.; Young, A.; Langdon, S.P. 2001: CA125 response and disease stabilisation are associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer. European Journal of Cancer 37(Suppl 6): S276-S277

O'brien, T.J.; Beard, J.B.; York, J.L. 2000: CA125 workshop Epitope mapping. Tumor Biology 21(Suppl 1): 83

Harlozinska, A.; Sedlaczek, P.; Grybos, M.; Einarsson, R. 2003: CA125, TPS and VEGF concentrations in sera, cyst and ascitic fluids of patients with ovarian neoplasms. Tumor Biology 24(Suppl 1): 79

Gesualdo, L.; Infante, B.; Guastadisegni, M.C.; Grandaliano, G.; Petrarulo, F.; Giannattasio, M.; Corciulo, R.; La Rosa, R.; Angelini, P.; Balestrazzi, A.; Schena, F.P. 2000: CA125/PAI-1 ratio as a marker of biocompatibility in CAPD A prospective randomized clinical trial. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 208A

Infante, B.; Guastadisegni, M.C.; Grandaliano, G.; Colucci, M.; Semeraro, N.; Petrarulo, F.; Giannattasio, M.; Corciulo, R.; Russo, R.; La Rosa, R.; Angelini, P.; Balestrazzi, A.; Gesualdo, L.; Schena, F.P. 2000: CA125/PAI-1 ratio may be a marker of peritoneal dialysis fluids biocompatibility and membrane longevity A clinical randomized prospective study. Nephrology Dialysis Transplantation 15(9): A238

Wong, R.C.W.; Klingberg, S.; Wilson, R. 2002: CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. Journal of rheumatology 29(9): 2021-2; author reply 2022

Ali, M.R.B.; Taamalli, H.; Machghou, S.; Rejeb, A.B.; Khdhiri, M.F.; Alaya, M.B.; Oueslati, R. 2000: CA15-3/CA19-9 and CEA profile in 147 serum patients of digestive tumors. Tumor Biology 21(Suppl 1): 130

Grazioli, V.; Rosazza, F.; Nunziatini, R.; Pallotti, G.; Arfini, C.; Dossena, P.; Ciardi, L.; Massari, L.; Bassan, M.; Tosatto, R.; Carraro, L. 2000: CA19-9 and CEA monitoring using Architect Interlaboratories and biological variation assessment. Tumor Biology 21(Suppl 1): 97

Lambrecht, R.M.; Morcos, N.; Yurt, F. 2001: CA19-9 tumor marker, CT and PET as 18 month status indicators of adenocarcinoma of the pancreas. Journal of Nuclear Medicine 42(5 Suppl): 263P

Zuppini, A.; Barbato, R.; Bergantino, E.; Dainese, P.; Meggio, F.; Martin, W.; Mariani, P. 1999: CA2+ binding protein calreticulin in Chlamydomonas reinhardtii Biochemical characterization, differential expression during sexual reproduction, and phylogenetic analysis. Journal of Phycology 35(6): 1224-1232

Irie, M.; Shi, X.Z.; Sarna, S.K. 1999: CA2+ mobilization by NK1 receptor activation in normal and inflamed colonic circular muscle cells. Gastroenterology 116(4 Part 2): A1011

Raastad, M.; Soleng, A.F.; Andersen, P. 1999: CA3 axons can conduct action potentials at high frequencies over long distances without failing. Society for Neuroscience Abstracts 25(1-2): 477

Yee, A.S.; Longacher, J.M.; Staley, K.J. 2000: CA3 bursting in 85mM K is a model for PLEDs. Epilepsia 41(Suppl 7): 11

Xiong, L.; Rouleau, G.A.; Delisi, L.E.; St-Onge, J.; Najafee, R.; Rivière, J.-B.; Benkelfat, C.; Tabbane, K.; Fathalli, F.; Danics, Z.; Labelle, A.; Lal, S.; Joober, R. 2005: CAA insertion polymorphism in the 3'UTR of Nogo gene on 2p14 is not associated with schizophrenia. Brain Research. Molecular Brain Research 133(1): 153-156

Lepage, S.; Boileau, G.; Lauzon, C.; Sauve, C.; Savard, D.; Rouleau, J.L.; Walling, A. 1999: Caaset. Journal of the American College of Cardiology 33(2 Suppl A): 340A

Walling, A.; Boileau, G.; Lepage, S.; Lauzon, C.; Sauve, C.; Savard, D.; Rouleau, J.L.cien 1999: CAASET Value of stress echo for comparative analysis. Journal of the American College of Cardiology 33(2 Suppl A): 474A

Delany, A.; Durant, D.; Canalis, E. 1999: CAAT enhancer binding proteins mediate down regulation of insulin-like growth factor I by cortisol in osteoblasts. Journal of Bone and Mineral Research 14(Suppl 1): S234

Lutter, G.; Buerkle, M.; Sarai, K.; Frey, M.; Saurbier, B.; Martin, J.; Nitzsche, E.; Zipfel, M.; Beyersdorf, F. 1999: CABG improves stress perfusion in contrast to TMLR in patients with endstage coronary disease. Circulation 100(18): I247-I248

Genoni, M.; Fries, P.; Tavakoli, R.; Odavic, D.; Kunzli, A.; Turina, M. 2002: CABG in women Higher risk?. European Heart Journal 23(Abstract Suppl): 440

Sweitzer, N.K.; Stevenson, L.W.; Gersh, B.J.; Dries, D.L. 2000: CABG reduces excess risk of death due to progressive heart failure in patients with diabetes and systolic dysfunction. Circulation 102(18): 2; 502

Gerlach, K.; Uhlig, T.; Saager, L.; Schmitz, A.; Schmucker, P. 2001: CABG surgery and effects of intraoperative opioids on emergence Remifentanil vs sufentanil. European Journal of Anaesthesiology 18(Suppl 21): 44

Bigger, J.T.; Rottman, J.N.; Whang, W.; Steinman, R.C.; Dimarco, J.P.; Cook, J.R.; Estes, N.A.M., IIi; Herre, J.M.; Cabg Patch Trial Investigators 1999: CABG surgery unlinked the arrhythmic substrate from arrhythmic outcomes in the CABG patch trial. Circulation 100(18): I366-I367

Kim, Y.H.; Mandal, A.; Farris, E.; Flickinger, C.J.; Herr, J.C. 2003: CABYR splice variants utilizing coding region A and coding region B are expressed in sperm and calcium binding occurs to isoforms containing only CR-A. Biology of Reproduction 68(Suppl 1): 350

Wehrens, R. 2002: CAC-2002 reflects diversity in applications. Trends in Analytical Chemistry 21(11): XXIV-XXVI

Esser, K.A.; Nelson, T.; Lupa Kimball, V.; Blough, E. 1999: CACC box and MEF2 sites within the MLC2slow promoter cooperate in regulating nerve specific transcription. FASEB Journal 13(4 Part 1): A411

Alonso, I.; Coelho, J.; Mendonca, P.; Jardim, L.; Tuna, A.; Barros, J.; Coutinho, P.; Sequeiros, J.; Silveira, I. 2000: CACNA1A gene polymorphisms in families with episodic ataxia and hemiplegic migraine. American Journal of Human Genetics 67(4 Suppl 2): 373

Wan, J.J.; Coulin, C.J.; Yu, H.F.; Kim, G.; Baloh, R.W.; Papazian, D.; Jen, J. 2001: CACNA1A mutations causing episodic ataxia type 2 lead to loss of function of the P/Q-type calcium channels in vitro. Neurology 56(8 Suppl 3): A439

Tikka, P.J.; Kaunisto, M.A.; Kallela, M.; Korhonen, A.; Hamalainen, E.; Farkkila, M.; Ophoff, R.; Palotie, A.; Wessman, M. 2003: CACNA1A or INSR are not major susceptibility loci in Finnish MA families. Cephalalgia 23(7): 662

Issa, Jean Pierre 2004: CACNA1G polynucleotide, polypeptide and methods of use therefor. Official Gazette of the United States Patent and Trademark Office Patents 1285(5)

Breneman, C.M.; Bennett, K.P.; Bi, J.; Embrechts, M.J.; Song, M. 2002: CACO-2 permeability modeling Feature selection via sparse support vector machines. Abstracts of Papers American Chemical Society 223(1-2): CINF 16

Mcgowan, C.M.; Chowdhry, S.N.; Gainey, W.E.; Moutray, K.L.; Bliven, B.; Alaswad, K.; Bateman, T.M. 1999: CAD prevalence in elderly asymptomatic patients Relation to risk factor clustering. Circulation 100(18): 1; 384

Kanazawa, K.; Helentjaris, T.; O'malley, D.M. 1999: CAD substrate specificity of defense response gene eli3 homologues in maize. Plant Biology (Rockville) : 132

Mori, K.; Aiguchi, T.; Ikezaki, M.; Kitasaka, T.; Suenaga, Y.; Toriwaki, J.I.; Mori, M. 2003: CAD system for quantitative evaluation of chronic obstructive pulmonary disease based on 3-D CT images. Lemke, Heinz U , Reprint Author, Vannier, Michael W, Inamura, Kiyonari, Farman, Allan G, Doi, Kunio, Reiber, John H C Computer assisted radiology and surgery: 1049-1054

Haganuma, A.; Obara, Y.; Nakahata, N. 2004: CAD, 5,19-cyclo-8beta, 10xi-androstane-3, 17-dione, as a potentiator of neurotrophic factor biosynthesis in glial cells mediated via protein kinase C-delta and epsilon. Journal of Pharmacological Sciences 94(Suppl 1): 284P

Schneider, W.; Rotgans, J. 2003: CAD/CAM repair in dentistry CEREC 3D. International Journal of Artificial Organs 26(7): 588

Zhang, Y.; Bell, T.W.; Samala, M.F.; Sodoma, A.; Princen, K.; De Clercq, E.; Schols, D. 2001: CADA A chemotherapeutic compound that inhibits HIV and HHV-7 replication by down-modulation of the CD4 receptor expression. Antiviral Research 50(1): A48

Bell, Thomas W.; Dey, Kaka; Jin, Qi; Samala, Meinrado F.; Scarbrough, Emily; Sodoma, Andrej; Vermeire, Kurt; De Clercq, Erik; Schols, Dominique 2001: CADA compounds Inhibitors of HIV and HHV-7 replication via down-modulation of CD4 receptor expression. Abstracts of Papers American Chemical Society 222(1-2): MEDI100

Azzarelli, B.; Miravalle, L.; Olson, J.; Ghetti, B.; Biller, J.; Vidal, R. 2003: CADASIL A familial form of cerebrovascular disease leading to dementia Identification of two new families and a novel mutation. Neurology 60(5 Suppl 1): A368-A369

D.D.ro, J.O.; Faccin, G. 2003: CADASIL Clinical and genetic features in a patient with migraine. Cephalalgia 23(7): 665

Viitanen, M.; Kalimo, H. 2000: CADASIL: hereditary arteriopathy leading to multiple brain infarcts and dementia. Annals of the new York Academy of Sciences 903: 273-284

Zurru, M.C.; Casas Parera, I.; Moya, G.; Giovanelli, C.; Genovese, O.; Gatto, E. 2002: CADASIL disease diagnosed by molecular DNA test. Medicina (Buenos Aires) 62(1): 48-52

Kalaria, R.N.; North East Cadasil Group 2002: CADASIL in British families. Journal of the Neurological Sciences (203-204): 307

Tabira, T.; Kotorii, S.; Santa, Y.; Takahashi, K. 2002: CADASIL in Japan and processing of Notch3 in transfected cells. Journal of the Neurological Sciences (203-204): 332

Camargo, C.H.nrique F.; Teive, H.A.; Raskin, S.; Coral, L.C.; Bordin Junior, M.; Pereira, E.T.; Trevisol Bittencourt, P.C.; Werneck, L.C.; Lesnik Oberstein, S.A.; Bakker, E.; Vollebregt, E.; Haan, J. 2001: CADASIL in a Brazilian family Clinical, radiologic, and genetic findings. Neurology 56(8 Suppl 3): A166

Cohen, B.A.; Quinn, B.; Meeks, J.J.; Kaplan, J.; Deng, H.X.; Siddique, T. 1999: CADASIL in an African-American family. Neurology 52(6 Suppl 2): A505

Mazzei, R.; Oliveri, R.L.; Conforti, F.L.; Patitucci, A.M.F.; Gabriele, A.L.; Magariello, A.; Muglia, M. 2000: CADASIL in an Italian family Clinical and genetic findings. Brain Pathology 10(4): 651

Mizuno, T.; Cookson, N.J.; Morris, C.M.; Kalaria, R.N. 1999: CADASIL linked-NOTCH3 mRNA expression in human brain vascular tissues and neural cell lines. Society for Neuroscience Abstracts 25(1-2): 1094

Joutel, A.; Andreux, F.; Francois, A.; Domenga, V.; Chapon, F.; Tournier Lasserve, E. 2000: CADASIL mutations impair the clearance of the Notch3 receptor. Journal of Submicroscopic Cytology and Pathology 32(3): 343

Stenner Liewen, F.; Liewen, H.; Zapata, J.M.; Reed, J.C. 2002: CADD, Chlamydia Agonist of Death Domains. Proceedings of the American Association for Cancer Research 43: 710

Graham, S.M.; Macaya, D.J.; Romano, A.E.; Sengupta, R.N.; Turner, K.B. 2003: CADPR analogs An NMR study on the effect of ribose ring modifications on conformation. Abstracts of Papers American Chemical Society 225(1-2): CARB 5

Graham, S.M.; Macaya, D.J.; Romano, A.E.; Sengupta, R.N.; Turner, K.B.; Zaborskis, C.A. 2003: CADPR analogs NMR studies, pseudorotational analysis, and in silico calculations of the effects of ribose ring modifications on conformation. Abstracts of Papers American Chemical Society 226(1-2): CARB 82

Graham, S.M.; Macaya, D.J.; Romano, A.E.; Sengupta, R.N.; Turner, K.B. 2002: CADPR analogs Synthesis, NMR structures, and conformational analysis. Abstracts of Papers American Chemical Society 224(1-2): CARB 8

Tolpekin, V.E.; Morozov, V.V.; Zhdanov, A.V.; Ganin, V.P.; Drobyshev, A.A. 2003: CAE simulation of hemodynamics and CAD/CAM design of artificial heart ventricles. International Journal of Artificial Organs 26(7): 668

Kilic, E.; Fernando, M.; Ziegeler, G.; Friedrich, M.; Sevinc, S.; Wurmbach, J.H.; Hammerer, P.; Wagener, C.; Erguen, S. 2002: CAECAM1 and its role in human urinary bladder cancer. Pathology Research and Practice 198(3): 140-141

Hillman, J.L.; Corley, N.C.; Yue, H. 2002: CAF1-related protein. Official Gazette of the United States Patent and Trademark Office Patents 1257(4)

Zeng, S.M.; Yankowitz, J. 2003: CAG repeat alteration and parental origin of the androgen receptor in Turner syndrome. American Journal of Human Genetics 73(5): 517

Vlasic, V.J.; Hecimovic, H.S.; Pavelic, P.K. 1999: CAG repeat analysis by expand long PCR in molecular diagnosis of Huntingtons disease. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S157

Fujigasaki, Hiroto; Durr, Alexandra; Martin, Jean J.; De Deyn, Peter P.; Camuzat, Agnes; Deffond, Didier; Brice, Alexis 2001: CAG repeat expansion in the TATA binding protein gene causes autosomal dominant cerebellar ataxia. Neurology 56(8 Suppl 3): A130

Casella, R.G.; Madura, M.R.; Zhao, Y.; Murthy, L.; Lamb, D.J.; Kolon, T. 2001: CAG repeat length in exon 1 of the androgen receptor gene of patients with cryptorchidism and/or hypospadias. Journal of Urology 165(5 Suppl): 146

Kote Jarai, Z.; Kadouri, L.; Durocher, F.; Easton, D.F.; Huber, A.; Abeliovich, D.; Glaser, B.; Peretz, T.; Eeles, R. 2001: CAG repeat length in the gene AIB1 gene modifies breast cancer risk in BRCA1/2 mutation carriers. American Journal of Human Genetics 69(4 Suppl): 274

Laurent, C.; Niehaus, D.; Soubigou, S.; Levinson, D.F.; Emsley, R.; Deleuze, J.F.; Mallet, J. 2001: CAG repeat polymorphisms in HSKCA3 and SCA12 show no association or linkage to schizophrenia but have shorter mean allele sizes in a Xhosa population. American Journal of Medical Genetics 105(7): 624

Hackel, C.; Ribeiro, M.L.; Mesquita, J.C.; Carvalho Salles, A.B. 2000: CAG repeats and Stu I polymorphism in the human androgen receptor gene and prostate cancer risk. European Journal of Human Genetics 8(Suppl 1): 100

Yasui, T.; Akita, H.; Itoh, Y.; Tozawa, K.; Ueda, K.; Kohri, K. 1999: CAG repeats in the androgen receptor: a case of spinal and bulbar muscular atrophy associated with prostate cancer. Journal of Urology 162(2): 495

Yu, H.; Bharaj, B.; Giai, M.; Diamandis, E.P. 1999: CAG repeats of the androgen receptor gene in breast cancer and its association with survival. Proceedings of the American Association for Cancer Research 40: 380

Messing, E.M.; Schoen, S.; Chang, C.; Fowler, J.E.; Bigler, S.A. 2001: CAG repeats within the androgen receptor gene in black and white men with local stage prostate cancer. Journal of Urology 165(5 Suppl): 142

Saluto, A.; Cagnoli, C.; Michielotto, C.; Gellera, C.; Castucci, A.; Mariotti, C.; Didonato, S.; Orsi, L.; Franco, A.; Rota, E.; Taroni, F.; Migone, N.; Brusco, A. 2002: CAG/CTG expansions are rare among patients with familial SCA not assigned to the SCA1-3,6-8,10,12,17 loci. American Journal of Human Genetics 71(4 Suppl): 553

Krause, A.; Temlett, J.; Van Der Meyden, K.; Ross, C.A.; Callahan, C.; Margolis, R.L. 2002: CAG/CTG repeat expansions at the HDL2 locus are a common cause of Huntington disease in black South Africans. American Journal of Human Genetics 71(4 Suppl): 528

Malysheva, O.; Ivaschenko, T.; Baranov, V. 2001: CAG/CTG repeat polymorphism of IT-15 and DMPK genes and prevalence of myotonic dystrophy and Huntington disease in different populations. European Journal of Human Genetics 9(Suppl 1): P0906

Xu, J.; Pato, M.T.; Dalla Torre, D.; Bauer, A.; Pato, C.N. 2000: CAG/CTG repeat polymorphisms on chromosomes 12q, 17q and 18q in schizophrenia and bipolar disorder in the Portuguese population. American Journal of Medical Genetics 96(4): 567-568

Klitz, W.; Barcellos, L.; Yuan, Q.P.; Lindblad, K.; Schalling, M.; Field, L.; Sheldin, M. 1999: CAG/CTG repeats in autoimmune disease A possible role in rheumatoid arthritis?. American Journal of Human Genetics 65(4): A278

Razdan, A.; Farin, G. 2003: CAGD methods for physical anthropology. American Journal of Physical Anthropology Suppl (36): 175

Kulpa, V.; Patton, A.M.; Libutti, S.K.; Kohn, E.C. 2002: CAI disrupts signaling between tumor and host environment in melanoma. Proceedings of the American Association for Cancer Research 43: 502-503

Kohn, E.C.; Liotta, L.A.; Kim, Y.S.ok 2004: CAI resistance proteins and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1286(2)

Hsu, Yen Ming 2002: CAIP-like gene family. Official Gazette of the United States Patent and Trademark Office Patents 1260(4)

Blanchette, J.; Doong, H.; Rizzo, K.; Kulpa, V.; Kohn, E.C. 2000: CAIR-1 expression is associated with distinct morphological phenotype in cancer cell lines. Proceedings of the American Association for Cancer Research 41: 786

Doong, H.; Blanchette, J.; Rizzo, K.; Kohn, E.C. 2000: CAIR-1, PLC-gamma and EGF-signaling pathway. Journal of Biomedical Science 7(2): 171

Doong, H.; Rizzo, K.; Kulpa, V.; Fang, S.Y.; Weissman, A.; Kohn, E. 2002: CAIR-1/BAG-3 regulates chaperone protein-mediated protein degradation. Proceedings of the American Association for Cancer Research 43: 887

Henley, J.M.; Nishimune, A. 2001: CAKbeta/Pyk2 activates Src: another piece in the puzzle of LTP induction. Neuron 29(2): 312-314

Salter, M.W. 2000: CAKbeta/Pyk2-Src kinase cascade in the regulation of NMDA receptors. European Journal of Neuroscience 12(Suppl 11): 61

Fisher, R.P. 1999: CAKs and CAKAKS CDK activation in fission yeast and mammals. Kidney International 56(4): 1184-1185

Winer, E.; Berry, D.; Duggan, D.; Henderson, I.C.; Cirrincione, C.; Cooper, M.R.; Norton, L. 1999: CALGB 9342 A randomized trial of three doses of paclitaxel in patients with metastatic breast cancer. Seminars in Oncology 26(6 Suppl 18): 9

Rubenwolf, S. 2002: CALI An innovative approach for the identification and validation of novel drug targets. Molecular and Cellular Proteomics 1(9): 722

Asnafi, V.; Radford Weiss, I.; Dastugue, N.; Bayle, C.; Leboeuf, D.; Charrin, C.; Garand, R.; Lafage Pochitaloff, M.; Troussard, X.; Macintyre, E. 2002: CALM-AF10 Is the Commonest Fusion Transcript in T-ALL and Is Specific to the TCRgammadelta Lineage. Blood 100(11): Abstract No. 2980

Qiu, K.; Su, Y.; Block, E.R. 2004: Calpain Sirna Function in Pulmonary Artery Endothelial cells. FASEB Journal 18(4-5): Abstract 221

Griffiths, H.; Maxwell, K.; Dodd, A.N. 2001: CAM Not so much a curiosity, more a lesson in integrated management. Photosynthesis Research 69(1-3): 156

Miszalski, Z.; Slesak, I.; Libik, M.; Surowka, E.; Pater, B.; Haag Kerwer, A.; Gawronska, K.; Karpinski, S.; Niewiadomska, E. 2003: CAM induction and oxidative stress in common ice plant. Free Radical Research 37(Suppl 2): 28-29

Bendelow, G.A. 2004: CAM what is it, which breast cancer patients use it and why?. EJC Suppls 2(3): 160

Jayasinghe, C.; Simiantonaki, N.; Kirkpatrick, C.J. 2001: CAM-expression on HUVEC after stimulation with supernatants of LPS- and cytokine-stimulated tumor cells. Journal of Cancer Research and Clinical Oncology 127(Suppl 1): S56

Simiantonaki, N.; Jayasinghe, C.; Kirkpatrick, C.J. 2000: CAM-expression on HUVEC after stimulation with supernatants of cytokine and LPS stimulated tumor cells. Pathology Research and Practice 196(6): 402

Eliceiri, K.W.; Thomas, C.; Rueden, C.; Stefansson, N.; Peterson, L.; Lu, F.M.; Chu, V.; Ron, A.; White, J.G. 2002: CAMBIO Computational algorithms for multidimensional biological image organization. Developmental Biology 247(2): 442

Racke, F.K.; Khetawat, R.; Zaidi, Z.; Moliterno, A.; Goldfarb, A.; Dang, C.V.n 2002: CAMP Agonist Forskolin Is a Potent and Selective Inhibitor of Megakaryocytic Differentiation of Primary Human Hematopoietic Stem Cells. Blood 100(11): Abstract No. 4173

Creighton, J.; Stevens, T. 2000: CAMP accumulation dictates calcium inhibition of adenylyl cyclase 6 necessary to increase gap formation in lung microvascular endothelial cells. FASEB Journal 14(4): A693

Yamaguchi, T.; Nagao, S.; Wallace, D.P.; Belibi, F.; Cowley, B.D.Jr; Pelling, J.C.; Grantham, J.J. 2001: CAMP activates extracellular signal-regulated kinase through B-Raf kinase activation in autosomal dominant polycystic kidney epithelial cells. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 548A

Podolski, J.L.; Lum, H. 2000: CAMP alters the organization of the actin cytoskeleton and the distribution of VE-cadherin in endothelial cells. FASEB Journal 14(4): A412

Scarparo, A.C.; Visconti, M.A.; Castrucci, A.M.L. 2002: CAMP and PKA are involved in the signalling pathway of alpha1-adrenoceptors in human melanoma cells. Pigment Cell Research 15(Suppl 9): 83

Hunter, L.W.; Jones, K.A.; Sieck, G.C.; Prakash, Y.S. 2002: CAMP and PKC regulation of cardiac Na+/Ca2+ exchange in neonates vs adults. FASEB Journal 16(4): A34

Sand, C.; Birken, S.; Weemink, P.A.O.de; Jakobs, K.H.; Schmidt, M. 2004: CAMP and Rap-regulated phospholipase C in B cells. Naunyn-Schmiedeberg's Archives of Pharmacology 369(Suppl 1): R51

Henkin, R.I.; Velicu, I.; Papathanissiu, A. 2003: CAMP and cGMP are both present in human nasal mucus and play roles in control of olfactory function. FASEB Journal 17(4-5): Abstract 647

Holler, M.; Schaffert, S.; Eckstein Ludwig, U.; Berk, A.; Clauss, W.; Schnizler, M. 2001: CAMP and glibenclamide stimulate amiloride-sensitive guinea-pig/Xenopus ENaC chimera. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R166

Ziemann, C.; Riecke, A.; Ruedell, G.; Hirsch Ernst, K.I.; Kahl, G.F. 2002: CAMP and protein kinase A activation participate in mdr1b up-regulation in primary rat hepatocytes. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R151

Burgoon, L.D.; Kwan, K.Y.; Trosko, J.E.; Zacharewski, T. 2003: CAMP and retinoic acid induced differentiation of human SVG cells Morphologic and transcriptional effects. Toxicological Sciences 72(S-1): 267

Nikolaeva, I.S.; Krupnova, E.P. 2003: CAMP as a primary and secondary messenger in the process of microorganisms and macroorganism interaction in pathological models related to immunodeficits and massive water loss by cells. Doklady Akademii Nauk 392(5): 710-712

Nagamatsu, T.; Nishiyama, T.; Goto, I.; Nagao, T.; Suzuki, Y. 2004: CAMP attenuates the production of fibronectin in glomeruli of nephritic rats. Journal of Pharmacological Sciences 94(Suppl 1): 260P

Martinez, J.A.; Banerjee, D.K. 1999: CAMP blocks apoptosis during tunicamycin-induced inhibition of angiogenesis in vitro. FASEB Journal 13(7): A1436

Wade, M.A.; Jones, R.C.; Murdoch, R.N.; Aitken, R.J. 2001: CAMP concentration increases during activation of motility in quiescent caudal epididymal sperm from the rat. Journal of Andrology (Suppl): 90

Gesta, S.; Daviaud, D.; Lafontan, M.; Valet, P.; Saulnier Blache, J.S. 2001: CAMP control of hypoxia-induced downregulation of adipocyte gene expression in human adipose tissue. International Journal of Obesity 25(Suppl 2): S48-S49

Waschke, J.; Drenckhahn, D.; Adamson, R.H.; Curry, F.E. 2004: CAMP counteracts the effect of Rac-1 inhibition on the endothelial barrier in vivo and in vitro. FASEB Journal 18(4-5): Abstract 195

Falck, A.J.; Castro, R.; Seidner, S.R.; Petershack, J.A.; Mendoza, Y.M.; Crichton, C.A.; Mustafa, S.B. 2002: CAMP improves deficient sodium channel and Na+K+ATPase expression and function in vivo and in vitro. Pediatric Research 51(4 Part 2): 396A

Reading, S.; Barclay, J.K. 2000: CAMP improves recovery of developed force in fatigued murine skeletal muscle. Biophysical Journal 78(1 Part 2): 431A

Reading, S.A.; Barclay, J.K. 2000: CAMP improves the recovery from fatigue in fast and slow murine skeletal muscle. FASEB Journal 14(4): A284

Lazrak, A.; Matalon, S. 2002: CAMP increases Na+ transport in respiratory epithelial cells by activating amiloride sensitive Na+ channels. FASEB Journal 16(4): A476

Kagawa, T.; Varticovski, L.; Arias, I.M. 2000: CAMP increases PI 3-kinase activity through PKA- and Gbetagamma- dependent- and phosphotyrosine- independent pathway. Molecular Biology of the Cell 11(Suppl): 247a-248a

Kannan, K.; Langston, J.W.; Kimpel, D.L.; Wolf, R.E. 2003: CAMP increases and inhibitors of PKA reduce pro-inflammatory cytokine production by human PBMC treated with PGPS. FASEB Journal 17(7): C270-C271

Alpini, G.; Glaser, S.; Francis, H.; Phinizy, J.L.; Chowdhury, U.; Lesage, G. 2000: CAMP increases ductal bile acid absorption by phosphoinositide 3-kinase-dependent translocation of the Na+-dependent apical bile acid transporter to the cholangiocyte apical membrane. Hepatology 32(4 Pt 2): 434A

Hug, M.J.; Sun, F.; Frizzell, R.A. 1999: CAMP increases membrane conductance and membrane capacitance in airway submucosal gland cells. Journal of General Physiology 114(1): 20a

Klar, J.; Sandner, P.; Mueller, M.W.H.; Kurtz, A. 2002: CAMP induced renin gene transcription in juxtaglomerular cells is mediated via the CRE binding protein. Pfluegers Archiv European Journal of Physiology 443(Suppl 1): S359

Gauther Stein, A.; Bady, I.; Mithieux, G.; Rajas, F. 2003: CAMP induces the transcriptional activity of the glucose-6-phosphatase gene in hepatocytes and enterocyte-like cells via CREB and HNF4alpha. Diabetologia 46(Suppl 2): A82

Lou, L.; Liu, L.; Xie, Y. 2003: CAMP inhibition of hepatoma cell proliferation is mediated by protein kinase B/Akt. Proceedings of the American Association for Cancer Research 44: 403

Boucher, M.J.; Duchesne, C.; Rivard, N. 2001: CAMP inhibits cell cycle progression and negatively modulates human intestinal cell differentiation. Gastroenterology 120(5 Suppl 1): A 498

Schlattjan, J.H.; Schmidt, E.; Greven, J. 2003: CAMP is involved in the regulation of the apical sodium-dependent bile acid transporter of the kidney. Naunyn-Schmiedeberg's Archives of Pharmacology 367(Suppl 1): R109

Papathanassiu, A.; Henkin, R.I.win 2002: CAMP is present in human nasal mucus and may act as a growth factor for cells of the olfactory epithelium. FASEB Journal 16(5): A1153

Cai, D.; Qiu, J.; Filbin, M.T. 1999: CAMP levels dictate the effect of myelin-associated glycoprotein on axonal regeneration during development and after injury. Society for Neuroscience Abstracts 25(1-2): 1001

Arai, M.; Thurman, R.G.; Lemasters, J.J. 1999: CAMP mediates protective preconditioning of sinusoidal endothelial cells against storage/reperfusion injury. Hepatology 30(4 Part 2): 312A

Morneau, F.; Dagenais, A.; Berthiaume, Y. 2002: CAMP modulates the effect of Pseudomonas aeruginosa-derived LPS on ENaC expression in alveolar epithelial cells. FASEB Journal 16(4): A412

Mcguire, S.O.; Counts, S.E.; Lum, H.; Sortwell, C.E.; Daley, B.F.; Collier, T.J. 2002: CAMP pretreatment increases the number of dopamine neurons in intrastriatal grafts. Journal of Neurochemistry 81(Suppl 1): 112

Khodair, M.A.; Zarbin, M.A.; Sugino, I.K.; Townes Anderson, E. 2001: CAMP prevents photoreceptor terminal retraction in full-thickness retinae and vibratomed retinal sheets prepared for transplantation. IOVS Investigative Ophthalmology and Visual Science 42(4): S782

Morris, R.G.; Schafer, J.A. 2001: CAMP produces proportional changes in short-circuit current and density of ENaC subunits in apical membrane of MDCK cells. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 37A

Akkerman, J.W.N.; Heemskerk, J.; Den Dekker, E. 2000: CAMP raises calcium in human megakaryocytes independent of protein kinase A. Blood 96(11 Part 2): 136b-137b

Qiao, J.; Lum, H. 2002: CAMP regulates Rho GTPase activity in endothelial cells. FASEB Journal 16(4): A437

Yamada, R.; Yamada, M.; Nishiyama, N.; Matsuki, N.; Ikegaya, Y. 2004: CAMP regulates Sema3F-induced growth cone collapse of axons and dendrites of dentate granule cells. Journal of Pharmacological Sciences 94(Suppl 1): 231P

Ameen, N.A.; Salas, P. 2001: CAMP regulates the number of CFTR channels on the cell surface of rat small intestinal epithelium by exocytosis. Gastroenterology 120(5 Suppl 1): A 310

D'souza, C.A.; Yue, C.; Cox, G.M.; Perfect, J.R.; Heitman, J. 2000: CAMP regulates virulence and mating via cAMP-dependent protein kinase A in the fungal pathogen Cryptococcus neoformans. Abstracts of the General Meeting of the American Society for Microbiology 100: 323

Cioffi, E.A.; Cioffi, D.L.; Stevens, T. 2002: CAMP resolution in endothelia using 31P nuclear magnetic resonance spectroscopy. FASEB Journal 16(4): A407

Balabanova, L.; Leffler, C.W. 2000: CAMP responses of piglet cerebral vascular smooth muscle to acidosis. FASEB Journal 14(4): A427

Gross, E.; Abuladze, N.; Pushkin, A.; Hopfer, U.; Kurtz, I. 2001: CAMP shifts the HCO3- Na+ stoichiometry of kNBC1 in proximal tubule cells. FASEB Journal 15(4): A502

Zhang, X.P.; Tada, H.; Xu, X.; Hintze, T.H. 2000: CAMP signal transduction, a potential compensatory pathway for coronary endothelial nitric oxide production in heart failure. Circulation 102(18): 2; 229

Naula, C.; Gong, K.; Shalaby, T.; Schaub, R.; Zoraghi, R.; Seebeck, T. 1999: CAMP signaling in Trypanosoma brucei A new target for new trypanocidal drugs?. Schweizerische Medizinische Wochenschrift 129(31-32): 1119

Seebeck, T.; Schaub, R.; Johner, A. 2004: CAMP signalling in the kinetoplastid protozoa. Current Molecular Medicine 4(6): 585-599

Perez, J.; Tardito, D.; Racagni, G.; Smeraldi, E.; Mori, S.; Zanardi, R. 2000: CAMP signalling system in the pharmacotherapy and pathophysiology of bipolar disorder. European Neuropsychopharmacology 10(Suppl 3): S143

Walker, N.M.; Flagella, M.; Gawenis, L.R.; Shull, G.; Clarke, L.L. 2000: CAMP stimulated anion secretion across NKCC1 knockout intestine. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A605

Wallace, D.P.; Thrasher, B.; Sullivan, L.P.; Grantham, J.J. 2000: CAMP stimulates anion and fluid secretion by medullary collecting duct cells from the human kidney. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 38A

Lesage, G.; Glaser, S.; Alvaro, D.; Kanno, N.; Phinizy, J.L.; Chowdury, U.; Alpini, G. 2000: CAMP stimulates secretory and proliferative capacity of the rat intrahepatic biliary epithelium through the PKA system. Gastroenterology 118(4 Suppl 2 Pt 1): AASLD A929

Niisato, N.; Ito, Y.; Marunaka, Y. 2000: CAMP stimulates sodium transport in rat fetal lung epithelium Involvement of a PTK-but not a PKA-dependent pathway. FASEB Journal 14(4): A338

Snyder, P.M. 1999: CAMP stimulates translocation of the epithelial sodium channel to the cell surface Disruption in Liddles syndrome. Circulation 100(18): 1; 846

Turner, H.C.; Alvarez, L.J.; Candia, O.A. 1999: CAMP stimulation of conjunctival Na absorption. IOVS Investigative Ophthalmology and Visual Science 40(4): S90

Orlov, S.N.; Thorin Trescases, N.; Dam, T.V.; Fortuno, M.A.; Dulin, N.; Tremblay, J.; Hamet, P. 1999: CAMP transiently inhibits apoptosis in vascular smooth muscle cells in a site upstream of caspase-3. FASEB Journal 13(5 Part 2): A832

Seino, S.; Ozaki, N.; Kashima, Y.; Iwanaga, T.; Shibasaki, T. 2001: CAMP-GEFII/Epac2 is a direct target of cAMP in regulated exocytosis. Cell Structure and Function 26(5): 337

Do, C.W.; Peterson Yantorno, K.; Mitchell, C.H.; Civan, M.M. 2003: CAMP-activated maxi-Cl- channels in native bovine pigmented ciliary epithelial cells Implications on the net secretion of aqueous humor. Journal of General Physiology 122(1): 42a

Adamska, M.; Huelster, A.; Oesch, F.; Oesch Bartlomowicz, B. 2002: CAMP-dependent Ah-receptor nuclear translocation and differential repression of its function. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R148

Zennadi, R.; Cartron, J.P.; Telen, M.J. 2003: CAMP-dependent activation of sickle red blood cell adhesion is associated with LW serine and tyrosine phosphorylation. Blood 102(11): 263a

Reading, S.; Barclay, J.K. 2002: CAMP-dependent changes in fatigue of Ca++-compromised mouse skeletal muscle in vitro. FASEB Journal 16(5): A774-A775

Nyquist Battie, C. 1999: CAMP-dependent modulation of 3H-norepinephrine uptake by a ventricular synaptosomal fraction isolated from rat heart. FASEB Journal 13(5 Part 2): A806

Ono, K.; Yano, M.; Yamamoto, T.; Hisaoka, T.; Tanigawa, T.; Kohno, M.; Ohkusa, T.; Matsuzaki, M. 1999: CAMP-dependent phosphorylation increases PN 200-110 binding to DHP receptor during membrane depolarization. Journal of the American College of Cardiology 33(2 Suppl A): 230A

Rhee, J.S.; Wang, Z.M.; Akaike, N. 1999: CAMP-dependent presynaptic regulation of spontaneous glycinergic IPSCs in the rat sacral dorsal commissural nucleus neurons. Society for Neuroscience Abstracts 25(1-2): 1259

Mizuhashi, S.; Yamada, M.; Nishiyama, N.; Ikegaya, Y.; Matsuki, N. 2001: CAMP-dependent protein kinase A signaling pathway is required for a target-specific axon guidance of hippocampal mossy fibers. Japanese Journal of Pharmacology 85(Suppl 1): 270P

Taylor, S.S.; Akamine, P.; Yang, J.; Wu, J.; Iyer, G.; Anand, G.; Valiev, M.; Weare, J.H.; Johnson, D.D. 2003: CAMP-dependent protein kinase Dynamics of catalysis and docking. Cellular and Molecular Biology Letters 8(2A): 545

Noble, E.G.; Melling, C.J.; Thorp, D.B. 2003: CAMP-dependent protein kinase activation of Hsp70 expression following exercise. Medicine and Science in Sports and Exercise 35(5 Suppl): S8

Taylor, A.P.; Abungu, B.; Adams, K.; Goldenberg, D.M.; Blumenthal, R.D. 2002: CAMP-dependent protein kinase and de novo transcription may regulate expression of placental growth factor. Proceedings of the American Association for Cancer Research 43: 10-11

Constantinescu, A.; Gordon, A.S.; Diamond, I. 2002: CAMP-dependent protein kinase isotypes I and II differentially regulate CRE-mediated gene expression; implications for neuronal responses to ethanol. Alcoholism Clinical and Experimental Research 26(5 Suppl): 10A

Crump, S.M.; Schroder, E.A.; Finlin, B.S.; Andres, D.A.; Satin, J. 2003: CAMP-dependent protein kinase modulates Rem-GTPase regulation of CaV12 expression via 14-3-3 protein. Circulation 108(17): IV241

Bencina, M.; Staudohar, M.; Panneman, H.; Ruitjer, G.J.; Visser, J.; Legisa, M. 2000: CAMP-dependent protein kinase of the fungus Aspergillus niger. Pfluegers Archiv European Journal of Physiology 439(3 Suppl): R90

Chen, S.H.; Tang, T.K. 2000: CAMP-dependent protein kinase phosphorylates the testis-specific protein kinase on threonine-171 within the activation loop. Molecular Biology of the Cell 11(Suppl): 249a-250a

Li, Z.; Ajdic, J.; Eigenthaler, M.; Du, X. 2002: CAMP-dependent protein kinase plays a predominant role in the cGMP-stimulated phosphorylation of vasodilator-stimulated phosphoprotein. Circulation 106(19): II150

Chang, A.; Li, P.P.; Warsh, J.J. 2003: CAMP-dependent protein kinase subunit mRNA levels in postmortem brain from patients with bipolar affective disorder. Molecular Brain Research 116(1-2): 27-37, 19 August

Constantinescu, A.; Gordon, A.S.; Diamond, I. 2003: CAMP-dependent protein kinase types I and II differentially regulate CRE-mediated gene expression implications for neuronal responses to ethanol. FASEB Journal 17(4-5): Abstract 648

Baldwin, A.E.; Sadeghian, K.; Kelley, A.E. 1999: CAMP-dependent protein kinases within the nucleus accumbens core mediate appetitive instrumental learning. Society for Neuroscience Abstracts 25(1-2): 638

Lorenz, D.; Maric, K.; Wiesner, B.; Betz, T.; Rosenthal, W. 2000: CAMP-dependent redistribution of the water channel aquaporin-2 investigated by capacitance and laser scanning reflection microscopic measurements. Naunyn-Schmiedeberg's Archives of Pharmacology 362(4-5 Suppl): R28

Holt, W.V.; Harrison, R.A.P. 1999: CAMP-dependent stimulation of boar sperm motility studied by CASA analysis. Journal of Reproduction and Fertility Abstract Series 23: 9

Alpini, G.; Glaser, S.; Chowdury, U.; Francis, H.; Kanno, N.; Phinizy, J.L.; Eisel, W.; Lesage, G. 1999: CAMP-dependent translocation of the apical bile acid transporter to the cholangiocyte apical membrane regulates ductal absorption of conjugated bile acids. Hepatology 30(4 Part 2): 418A

Chepurny, O.; Holz, G. 2003: CAMP-independent signaling properties of exendin-4 and Gs-alpha in support of insulin gene promoter activity. Diabetes 52(Suppl 1): A365

Bindewald, K.; Guenduez, D.; Nau, S.; Klingenberg, D.; Noll, T. 2001: CAMP-induced barrier failure in microvascular coronary endothelial cells is due to disintegration of cell-cell adhesion but not activation of the contractile apparatus. Circulation 104(17): 2; 273

Srinivas, S.P.; Goon, L.H.; Loo, A.; Goon, L.; Bonanno, J.A. 2000: CAMP-induced changes in cell volume of corneal endothelial cells. IOVS Investigative Ophthalmology and Visual Science 41(4): S523

Van Dyke, R.W.; Barns, D.W.; Lewis, M.R. 2002: CAMP-induced changes in liver endocytosis are associated with phosphorylation of the protein kinase B effectors glycogen synthase kinase-3 and FOXO transcription factors. Hepatology 36(4 Part 2): 240A

Goon, L.H.; Srinivas, S.P.; Goon, L.; Thotz, S.Y.; Yue, B.Y.J.T. 2000: CAMP-induced changes in the cell volume of trabecular meshwork cells. IOVS Investigative Ophthalmology and Visual Science 41(4): S575

Bindewald, K.; Guenduez, D.; Klingenberg, D.; Piper, H.M.; Noll, T. 2002: CAMP-induced increase in macromolecule permeability in microvascular coronary endothelial cells is due to disintegration of cell-adhesion but not activation of the contractile apparatus. Pfluegers Archiv European Journal of Physiology 443(Suppl 1): S199

Harayama, H.; Sasaki, K.; Miyake, M. 2004: CAMP-induced increase of 32-kDa tyrosine-phosphorylated protein is related to the calcium-dependent disintegration of the acrosome in boar sperm. Journal of Andrology Suppl (Suppl): 44

Misra, S.; Ujhazy, P.; Arias, I.; Varticovski, L. 1999: CAMP-induced recruitment of spgp and mrp2 is mediated by G-protein associated PI 3-kinase. Hepatology 30(4 Part 2): 306A

Wuechner, K.; Bachmann, O.; Rossmann, H.; Gregor, M.; Seidler, U. 2001: CAMP-mediated activation of NBC and NKCC in murine colonic crypts. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R131

Paunescu, T.G.; Helman, S.I. 2001: CAMP-mediated increases of membrane capacitance in A6 epithelia. FASEB Journal 15(5): A837

Smith, P.R. 1999: CAMP-mediated regulation of amiloride-sensitive sodium channels Channel activation or channel recruitment?. Benos, D J Current Topics in Membranes; Amiloride-sensitive sodium channels: Physiology and functional diversity 133-154

Korniotis, N.; Wilderspin, A.F. 2000: CAMP-specific Phosphodiesterase IVA1 expression in a mammalian system. Biochemical Society Transactions 28(3): A76

Morgan, S.R.; Perry, M.; Mathialahan, T.; Boot Handford, R.P.; Sandle, G.I. 1999: CAMP-stimulated human renal Na+ channel activity is independent of membrane vesicle fusion in Xenopus oocytes. Journal of Physiology (Cambridge) 517P: 68P-69P

Shiue, M.H.I.; Kim, K.J.; Loo, D.D.F.; Lee, V.H.L. 1999: CAMP-stimulation of whole cell chloride current in the rabbit conjunctival epithelial cells. FASEB Journal 13(4 Part 1): A59

Sussmann, M.; Meyer Kirchrath, J.; Schroer, K.; Fischer, J.W. 2003: CAMP/PKA dependent induction of hyaluronic acid synthase-2 in human vascular smooth muscle cells by IP- and EP2-receptor ligands. Circulation 108(17): IV193

Carpenter Hyland, E.; Odonnell, J.; Chandler, J. 2002: CAMP/PKA signaling and synaptic targeting of NMDA receptors. Alcoholism Clinical and Experimental Research 26(5 Suppl): 10A

Jeffries, O.; McGahon, M.K.; Bankhead, P.; Lozano, M.Manfredi.; Scholfield, C.Norman.; Curtis, T.M.; McGeown, J.Graham. 2010: cAMP/PKA-dependent increases in Ca Sparks, oscillations and SR Ca stores in retinal arteriolar myocytes after exposure to vasopressin. IOVS Investigative Ophthalmology and Visual Science 51(3): 1591-1598

Ewing, G.; Rogers, M.; Todd, C.; Mccabe, J.; Martin, A.; Barclay, S. 2001: CAMPAS New instrument for measuring symptoms and needs for cancer patients at home Measurement characteristics for anxiety and depression scales. European Journal of Cancer 37(Suppl 6): S430

Rogers, M.; Ewing, G.; Todd, C.; Martin, A.; Barclay, S.; Mccabe, J. 2001: CAMPAS New instrument for measuring symptoms and needs for cancer patients at home Measurement characteristics for pain. European Journal of Cancer 37(Suppl 6): S430-S431

Todd, C.; Ewing, G.; Rogers, M.; Barclay, S.; Mccabe, J.; Martin, A. 2001: CAMPAS New instrument for measuring symptoms and needs for cancer patients at home Measurement characteristics for symptoms. European Journal of Cancer 37(Suppl 6): S404

Devereux, S.; Parker, J.E.; Shafi, T.; Pagliuca, A.; Macdonald, E.; Mufti, G.J. 2001: CAMPATH-1H reduces the risk of graft versus host disease following allogeneic hematopoietic stem cell transplantation and minimally myelosuppressive conditioning treatment with low dose total body irradiation and Cyclosporine/Mycophenolate Mofetil immunosuppression. Blood 98(11 Part 2): 355b-356b

Graeven, U.; Ridwelski, K.; Manns, M.P.; Espana, P.; Carlsson, G.; Borner, M.; Boussard, B.; Oulid Aissa, D.; Hemmers, H.; Schmiegel, W.H. 1999: CAMPTO combined with different schedules of bolus 5-FU in 1st line treatment of metastatic colorectal cancer. European Journal of Cancer 35(Suppl 4): S79

Nevell, D.G.; Wagenaar, J.A.; Duim, B.; Van Der Plas, J.; On, S.L.W. 2001: CAMPYNET The origin and typing of the international reference strain set. IJMM International Journal of Medical Microbiology 291(Suppl 31): 168

Pienta, K.J.; Abbott, R.; Forrest, S. 2002: CANCERGRID A computer simulation of cancer phenotypes. Proceedings of the American Association for Cancer Research 43: 896

Sebaldt, R.J.; Adachi, J.D.; Olszynski, W.; Brown, J.P.; Hanley, D.A.; Josse, R.G.; Murray, T.; Stephenson, G.F.; Petrie, A.; Mark, A.; Goldsmith, C.H. 2002: CANDOO A longitudinal Canadian multi-center tertiary-care network for observational research in osteoporosis and osteopenia using standardized clinical practice data 11 Years of follow-up. Journal of Bone and Mineral Research 17(Suppl 1): S358

Wade, M.R.; Tzavara, E.T.; Nomikos, G.G. 2004: Cannabinoids reduce cAMP levels in the striatum of freely moving rats: an in vivo microdialysis study. Brain Research 1005(1-2): 117-123

Spinelli, S.; Ballard, T.M.; Higgins, G.A.; Feldon, J.; Pryce, C.R. 2003: CANTAB-based attention and memory studies in the common marmoset monkey. Journal of Psychopharmacology 17(Suppl 3): A60

Hasegawa, N.; Okada, K.; Abe, H. 2000: CAP binds to monomeric actin associated with ADF/cofilin. Cell Structure and Function 25(6): 530

Kimura, A.; Baumann, C.A.; Chiang, S.H.; Saltiel, A.R. 2001: CAP defines a novel signaling pathway in the regulation of glucose transport. Diabetes 50(Suppl 2): A278

Sparks, S.D. 2001: CAP inspection: two frequently problematic questions. Cytometry 46(5): 307-309

Goldman, R.; Lai, C.; Day, B.W.; Carver, T.A.; Mauthe, R.J.; Turteltaub, K.W.; Shields, P.G. 1999: CAP14C-postlabeling of DNA adducts combined with accelerator mass spectrometric detection. Proceedings of the American Association for Cancer Research 40: 152

Hirata, M.; Kirikae, T.; Tamura, H.; Tanaka, S.; Wright, S.C.; Larrick, J.W. 1999: CAP18-derived peptides show anti-endotoxin and anti-microbial activity. Journal of Leukocyte Biology (Suppl ): 24

Xu, H.; Hebert, M.D. 2003: CAP36C A novel protein implicated in snRNP maturation and regeneration?. Molecular and Cellular Proteomics 2(9): 902

Ruan, X.; Chodosh, J.; Lerner, M.; Brackett, D.; Pereira, H. 2001: CAP37, a multifunctional inflammatory mediator promotes corneal epithelial cell proliferation and migration. IOVS Investigative Ophthalmology and Visual Science 42(4): S887

Huang, X.; Boysen, C.; Herrmannsfeldt, G.; Qian, J.; Smith, C.P. 2000: CAP4 sequence assembly program. International Genome Sequencing and Analysis Conference 12: 67

Parks, B. 1999: CAP88-PC version 20. Health Physics 76(6 Suppl): S188

Saez, J.; Martinez, J.; Trigo, C.; Grino, P.; Garcia, C.; Laveda, R.; Company, L.; Perez Mateo, M. 2000: CAPAP as diagnostic and prognostic factor in acute pancreatitis. Digestion 61(4): 289

Rocco, M.; Flanigan, M.; Frankenfield, D.; Frederick, P.; Prowant, B.; Bailie, G. 1999: CAPD adequacy and prescription data in a national cohort sample The 1998 Health Care Financing Administration ESRD Peritoneal Dialysis Core Indicators Study. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 337A

Rocco, M.; Flanigan, M.; Frankenfield, D.; Frederick, P.; Prowant, B.; Bailie, G. 2000: CAPD adequacy data in a national cohort sample The 1999 Health Care Financing Administration ESRD Peritoneal Dialysis Clinical Performance Measures. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 217A

Grzegorzewska, A.E.; Antczak Jedrzejczak, D.; Leander, M. 2002: CAPD adequacy parameters during the treatment with polyglucose dialysis solution. Nephrology Dialysis Transplantation 17(Abstracts Suppl 1): 163-164

Naicker, S.; Botden, L.; Madala, N.D.; Naiker, I.P. 2002: CAPD in South Africa , a single center experience. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 714A

Heaf, J.G. 1999: CAPD is contraindicated for patients with high peritoneal transport characteristics. Nephrology Dialysis Transplantation 14(9): A234

Enia, G.; Tripepi, G.; Mallamaci, F.; Benedetto, F.A.; Bonanno, G.; Candela, V.; Fatuzzo, P.; Rapisarda, F.; Seminara, G.; Stancanelli, B.; Giacone, G.; Cottini, E.; Bellanuova, I.; Cataliotti, A.; Cutrupi, S.; Postorino, M.; Parlongo, S.; Tripepi, R.; Malatino, L.; Zoccali, C. 1999: CAPD patients are volume expanded and display more severe LVH than hemodialysis patients CREED Investigators. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 260A

Enia, G.; Mallamaci, F.; Benedetto, F.A.; Cottini, E.; Giacone, G.; Tripepi, G.; Bonanno, G.; Fatuzzo, P.; Rapisarda, F.; Seminara, G.; Cutrupi, S.; Parlongo, S.; Malatino, L.; Zoccali, C. 2000: CAPD patients on long term treatment are volume expanded and display more severe left ventricular hypertrophy than hemodialysis patients. Nephrology Dialysis Transplantation 15(9): A238

Fitzpatrick, L.R.; Wang, J.; Le, T. 2001: CAPE, an inhibitor of nuclear factor-kappa B , attenuates bacterial peptidoglycan polysaccharide induced colitis in rats. Gastroenterology 120(5 Suppl 1): A 685

Fodstad, O.; Hovig, E.; Engebraaten, O.; Maelandsmo, G.; Agrawal, S.; Von, H., E. 1999: CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer. Official Gazette of the United States Patent and Trademark Office Patents 1220(1): 575

Snyder, S.H.; Jaffrey, S.R. 2000: CAPON a protein associated with neuronal nitric oxide synthase. Official Gazette of the United States Patent and Trademark Office Patents 1237(3)

Largo, R.; Rosa, A.; Terzano, M.; Parrino, L.; Smerieri, A. 2002: CAPS detection and classification using wavelets. Journal of Sleep Research 11(Suppl 1): 133

Elhamdani, A.; Martin, T.F.J.; Artalejo, C.R. 1999: CAPS is critical for the fusion of catecholamine dense-core vesicles with the membrane in chromaffin cells. Biophysical Journal 76(1 Part 2): A400

Artalejo, C.R.; Martin, T.F.J.; Elhamdani, A. 1999: CAPS is critical for the fusion step of dense-core vesicle exocytosis in calf adrenal chromaffin cells. Society for Neuroscience Abstracts 25(1-2): 2070

Tinembart, O.; Tashiro, S. 2000: CAPSTARTM A new systemic flea adulticide for cats and dogs. Agrochemicals Japan 76: 7-10

Finberg, R.W.; Bergelson, J.M.; Horwitz, M.S. 2001: CAR a novel coxsackievirus and adenovirus receptor. Official Gazette of the United States Patent and Trademark Office Patents 1245(1)

Gras, E.J.; Krom, Y.D.; Frants, R.R.; Havekes, L.M.; Biessen, E.A.; Van Dijk, K.W.llems 2003: CAR-avidin as a novel tool to target adenovirus vectors to cells involved in atherosclerosis. Circulation 108(17): IV176

Johnson, A.L.; Bridgham, J.T. 1999: CAR1, a novel member of the TNF receptor family that mediates ovarian granulosa cell apoptosis. Biology of Reproduction 60(Suppl 1): 219

Wright, C.L.; Kaple, M.L.; Burgoon, P.W.; Boulant, J.A. 2004: Carbon Dioxide and Ph effects on Hypothalamic Thermoregulatory Neurons. FASEB Journal 18(4-5): Abstract 704

Russell, R.K.; Wilson, D.C.; Satsangi, J. 2004: CARD 15 / NOD 2 in paediatric onset Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition 39(2): 216

Damiano, J.S.; Reed, J.C. 2004: CARD proteins as therapeutic targets in cancer. Current Drug Targets 5(4): 367-374

Pathan, N.; Pio, F.; Kitada, S.; Krajewska, M.; Krajewski, S.; Godzik, A.; Reed, J.C. 2001: CARD10, a novel anti-apoptotic card-containing protein. Proceedings of the American Association for Cancer Research 42: 553

Peters, K.E.; Cavanaugh, J.A. 2004: CARD15 and Crohn's disease. Journal of Gastroenterology and Hepatology 19(7): 830

Lesage, S.; Zouali, H.; Merlin, F.; Chamaillard, M.; Cezard, J.; Belaiche, J.; Almer, S.; Tysk, C.; O'morain, C.; Gassull, M.; Binder, V.; Modigliani, R.; Gower Rousseau, C.; Colombel, J.; Thomas, G.; Hugot, J. 2002: CARD15 mutations in families with mixed Inflammatory Bowel Disease. European Journal of Human Genetics 10(Suppl 1): 82

Marks, D.J.B.; Joshi, M.; Harbord, M.; Bloom, S.; Segal, A.W. 2003: CARD15 variants associated with Crohns disease result in impairment in the up-regulation of chemotactic cytokines. European Cytokine Network 14(Suppl 3): 59

Zouali, H.; Lesage, S.; Merlin, F.; Cezard, J.P.; Colombel, J.F.; Belaiche, J.; Almer, S.; Tysk, C.; O'morain, C.; Gassull, M.; Modiglian, R.; Gower Rousseau, C.; Chamaillard, M.; Thomas, G.; Hugot, J.P. 2002: CARD4/NOD1 in inflammatory bowel disease. American Journal of Human Genetics 71(4 Suppl): 490

Guo, W.; Kim, H.J.; Wewers, M.D. 2002: CARDIAK interacts with caspase-1 during endotoxin activation of human monocytes. FASEB Journal 16(4): A292

Guo, W.; Kim, H.J.; Wewers, M.D. 2003: CARDIAK is involved in multiple signal transduction pathways during LPS activation of human monocytes. FASEB Journal 17(7): C157

Matangi, M.; Barber, G. 2001: CARDIOfile A cardiology database, reporting and billing system. European Heart Journal 22(Abstract Suppl): 501

Rezakovic, D.Z.E.; Stipic, A. 1999: CARDIOnet Program, education-information program in cardiovascular medicine on Internet. European Heart Journal 20(ABSTR Suppl ): 308

Jacobs, B.; Young, N.L.; Dick, P.T.; Ipp, M.M.; Dutkowski, R.; Davies, D.; Langley, J.M.; Greenberg, S.; Stephens, D.; Wang, E.E.L. 1999: CARIFS The Canadian acute respiratory illness and flu scale. Pediatric Research 45(4 Part 2): 103A

Van Der Velde, E.T.; Witteman, T.A.; Foeken, H.; Brobbel, C.; Kalshoven, M.; Louwerse, C.; Atsma, D.E. 2003: CARIS-NT Development of a multi-tier, component-based multicentre Cardiology Information System to support regional healthcare. European Heart Journal 24(Abstract Suppl): 141

Raju, J. 2001: CARK protein and nucleic acid molecules and uses therefor. Official Gazette of the United States Patent and Trademark Office Patents 1248(3)

Havelaar, A.; Bogaardt, M.; Cooke, R.; Evers, E.; Van Der Fels Klerx, I.; Goossens, L.; Jacobs Reitsma, W.; De Jong, M.; Mangen, M.; Mylius, S.; Nauta, M.; Van Pelt, W.; Schijven, J.; Stegeman, H.; Wagenaar, J.; De Wit, A. 2003: CARMA A multidisciplinary approach to controlling campylobacteriosis. IJMM International Journal of Medical Microbiology 293(Suppl 35): 26

Mylius, S.; Nauta, M.; Havelaar, A. 2003: CARMA Modelling the transmission of Campylobacter in the consumer phase. IJMM International Journal of Medical Microbiology 293(Suppl 35): 28

Caffo, A.L.; Mortimer, R.M. 2003: CARP A calcium rich precipitate causes errors in the analysis of calcium. Clinical Chemistry 49(S6): A95

Kanai, H.; Tanaka, T.; Aihara, Y.; Takeda, S.I.; Kurabayashi, M. 2001: CARP inhibits cellular proliferation through the p53-dependent p21WAF1/CIP1 pathway. Circulation 104(17): 2; 323

Boengler, K.; Deindl, E.; Neubauer, E.; Fernandez, B.; Pipp, F.; Schaper, W. 2001: CARP is upregulated in growing collateral arteries. Journal of Molecular and Cellular Cardiology 33(6): A15

Zolk, O.; Maurer, A.; Marx, M.; El Armouche, A.; Kluxen, F.W.; Hentsch, B.; Eschenhagen, T.; Hoheisel, J.; Frohme, M. 2001: CARP, a negative regulator of cardiac gene expression, is upregulated in human heart failure. European Heart Journal 22(Abstract Suppl): 540

Basu, S.; Basu, M.; Ghosh, S.; Dastgheib, S.; Basu, S.S. 2000: CARS and HY-CARS glycosyltransferases in glycolipid biosynthesis. Glycoconjugate Journal 17(1-2): 22

Tornoe, K.; Orskov, C.; Clausen, J.T.; Thim, L.; Wulff, B.S.; Holst, J.J. 1999: CART ; A new neurotransmitter in the porcine gastrointestinal tract. Gastroenterology 116(4 Part 2): A1093

Adams, L.D.; Gong, W.; Vechia, S.D.; Hunter, R.G.; Kuhar, M.J. 1999: CART: from gene to function. Brain Research 848(1-2): 137-140

Bourg, N.A.; Mcshea, W.J.; Gill, D.E.; Koy, K. 2003: CART and GIS-based predictive habitat modeling for Turkeybeard , a rare fire-adapted Appalachian forest herb. Ecological Society of America Annual Meeting Abstracts 88: 40

Hunter, R.G.; Kuhar, M.J. 2004: CART mRNA in the Rat Nucleus Accumbens is Down-regulated Via D3 Dopamine Receptors. FASEB Journal 18(4-5): Abstract 162

Vicentic, A.; Hunter, R.; Philpot, K.; Dominguez, G.; Kuhar, M. 2004: CART peptide levels in the brain exhibit a diurnal rhythm and are influenced by fasting. FASEB Journal 18(4-5): Abstract 394

Kuhar, M.J.; Gong, W.; Adams, L.; Dall Vechia, S.; Hunter, R.; Elmquist, J. 1999: CART peptides and feeding. Brain Research 848(1-2): A19

Hunter, R.G.; Kuhar, M.J. 2003: CART peptides as targets for CNS drug development. Current Drug Targets. Cns and Neurological Disorders 2(3): 201-205

Koylu, E.O.; Smith, Y.; Couceyro, P.R.; Kuhar, M.J. 1999: CART peptides colocalize with tyrosine hydroxylase neurons in rat locus coeruleus. Synapse 31(4): 309-311

Couceyro, P.R.; Fritz, T. 1999: CART peptides induce c-fos expression in cultured pituitary cells. Society for Neuroscience Abstracts 25(1-2): 2222

Murphy, K.G.; Taheri, S.; Abbott, C.R.; Rossi, M.; Kuhar, M.; Ghatei, M.; Bloom, S.R. 2000: CART-like immunoreactivity in the CNS Distribution, quantification and changes with fasting in Wistar rats. Journal of Endocrinology 164(Suppl ): P177

Peiro, G.; Diebold, J.; Baretton, G.B.; Kimmig, R.; Loehrs, U. 2001: CAS , Bcl-2, Bax, and Caspase-3 expression and prognosis in sporadic endometrial carcinoma. Laboratory Investigation 81(1): 143A

Peiro, G.; Diebold, J.; Baretton, G.B.; Loehrs, U. 2001: CAS expression in ovarian carcinoma Correlation with 20q132 , and Cyclin D1, p53, and Rb expression. Laboratory Investigation 81(1): 143A

Muders, M.H.; Aust, D.E.; Baretton, G.B.; Loehrs, U. 2003: CAS/CSE1 protein expression in colorectal carcinomas Correlation with prognosis, survival and 20q132 gain. Proceedings of the American Association for Cancer Research 44: 242

Janbon, G.; Provost, F.; Dromer, F. 2000: CAS1 is a membrane protein necessary for the synthesis of a Cryptococcus neoformans capsule sugar epitope. Abstracts of the General Meeting of the American Society for Microbiology 100: 51

Eim, B.J.; Zavodna, R. 1999: CASA The specific tumor marker in preoperative diagnosis of the risk adnex masses before endoscopy. Anticancer Research 19(6D): 5691

Froldi,R.; Croci,P.F.; Dell'Acqua,L.; Fare,F.; Tassoni,G.; Gambaro,V. 2010: CASE REPORT preliminary gas chromatography with mass spectrometry determination of 3,5-dimethoxyphenol in biological specimens as evidence of Taxus poisoning. Journal Of Analytical Toxicology: 1, 53-56

Drouin, D.; Couture, A.R.; Gauvin, R.; Horny, P. 2001: CASINO V20 A fast and easy-to-use tool for scanning electron microscope users. Scanning 23(2): 93-94

Muders, M.; Aust, D.E.; Baretton, G.B.; Loehrs, U. 2003: CASP/CSE1 expression in colorectal carcinomas Correlation with prognosis and survival. Pathology Research and Practice 199(4): 282

Pidasheva, S.; D'souza Li, L.; Cole, D.E.C.; Hendy, G.N. 2002: CASRdb, calcium sensing receptor locus-specific database for mutations causing familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism and autosomal dominant hypocalcemia. Journal of Bone and Mineral Research 17(Suppl 1): S494

Borelli, S.; Anliker, M.D.; Bucher, C.; Wuthrich, B. 2001: CAST-ELISA is not useful for monitoring of hymenoptera venom immunotherapy Results of a 3-year prospective study. Allergy 56(Suppl 68): 13

Barber, T.D.; Friedman, T.B. 1999: CASTing for genes regulated by PAX3 during embryonic development and cancer epigenesis. American Journal of Human Genetics 65(4): A181

Gruen, J.; Raha Chowdhury, R. 2003: CAT 53 A protein phosphatase 1 nuclear targeting subunit encoded in the MHC Class 1 region may take part in memory and learning. American Journal of Human Genetics 73(5): 342

Jordania, R.; Bartsch, O.; Zorjanova, T.; Kallas, L.; Rattasep, E.; Uibo, K. 2002: CATCH phenotype 6 Cases from Estonia, three confirmed by FISH. European Journal of Human Genetics 10(Suppl 1): 121

Osaki, Y.; Oana, S.; Yasukawa, K.; Fujimori, K.; Terai, M.; Niimi, H. 2000: CATCH22 syndrome with gastroesophageal reflux. Pediatrics International: Official Journal of the Japan Pediatric Society 42(4): 367-368

Moore, C.B.; Lich, J.D.; O'connor, W.; Conti, B.; Ting, J. 2004: CATERPILLER 113 A novel protein involved in NF kappa B activation. FASEB Journal 18(4-5): Abstract 89

Davis, B.K.; Brickey, W.J.; Sartor, R.B.; Ting, J.P. 2004: CATERPILLER 161 and active colitis. FASEB Journal 18(4-5): Abstract 331

Cheng, K.W.; Mills, G.B. 2002: CATX-8/Rab 25 regulates growth of ovarian cancer cells. Proceedings of the American Association for Cancer Research 43: 355-356

Freeman, K.B.; Nicholas, R.O.; Livi, G.P. 1999: CAYAE1 polynucleotides. Official Gazette of the United States Patent and Trademark Office Patents 1219(2): 1528

Anonymous 2000: CAb series 1 to 10; GST-ING. Hybridoma 19(3): 280

Wei, J.; Layne, M.D.; Yet, S.F.ng 2003: CArG box-independent expression of cysteine-rich protein 2 promoter in the developing vasculature. Circulation 108(17): IV203

Strobeck, M.; Du, K.; Zhang, J.C.L.; Tang, Z.; Kim, S.; Parmacek, M.S. 2000: CArG box-specificity restricts gene expression to arterial smooth muscle cells in transgenic mice. Circulation 102(18): 2; 359

Forsythe, S.M.; Camoretti Mercado, B.; Liu, H.W.; Halayko, A.J.; Go, L.; Kao, A.; Solway, J. 1999: CArG-containing enhancers in the first intron of the human smooth muscle myosin heavy chain gene. FASEB Journal 13(4 Part 1): A169

Knox, R.J.; Burke, P.J.; Chen, S.; Kerr, D.J. 2003: CB 1954: from the Walker tumor to NQO2 and VDEPT. Current Pharmaceutical Design 9(26): 2091-2104

Theobald, R.J.; Geisbuhler, T.P. 2004: CB1 Receptor Antagonist SR141716A Effects in Detrusor Smooth Muscle. FASEB Journal 18(4-5): Abstract 403

Clayton, N.M.; O'shaughnessy, C.T.; Marshall, F.; Bountra, C. 2001: CB1 and CB2 cannabinoid receptors are implicated in inflammatory hypersensitivity to pain. British Journal of Pharmacology 134(Proceedings Suppl): 18P

Hillard, C.J.; Muthian, S.; Gross, G.J. 2003: CB1 cannabinoid receptor blockade is protective against transient focal cerebral ischemia. Journal of Neurochemistry 87(Suppl 1): 134

Prescilla, R.P.; Hao, H.N.; Aranda, J.V.; Lyman, W. 2001: CB1 cannabinoid receptor expression in human fetal brain. Pediatric Research 49(4 Part 2): 456A

Brotchie, J.M. 2003: CB1 cannabinoid receptor signalling in Parkinson's disease. Current Opinion in Pharmacology 3(1): 54-61

Begg, M.; Nelemans, S.A.; Molleman, A. 1999: CB1 cannabinoid receptor-mediated activation of K+ current in DDT1MF-2 cells is entirely dependent on the presence of extracellular Ca2+. British Journal of Pharmacology 128(Proceedings Suppl ): 140P

Szabo, B. 2003: CB1 cannabinoid receptors mediate presynaptic inhibition of neurotransmission. Polish Journal of Pharmacology 55(3): 513-514

Kathmann, M.; Liedtke, S.; Schlicker, E. 2002: CB1 receptor deficiency increases noradrenaline release in the mouse vas deferens. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R79

Van Vliet, B.J.; Nievelstein, H.N.M.W.; Long, S.K.; Kruse, C.G. 2000: CB1 receptor mediated effects on brain neurotransmitter systems. European Neuropsychopharmacology 10(Suppl 3): S182-S183

Winsauer, P.J.; Moerschbaecher, J.M. 1999: CB1-receptor ligands differentially disrupt complex behavioral processes in monkeys. FASEB Journal 13(5 Part 2): A1109

Rinaldi, M.; Barth, F.; Casellas, P.; Congy, C.; Oustric, D.; Bell, M.R.; D'ambra, T.E.; Philion, R.E. 2000: CB2 Receptor agonist compounds. Official Gazette of the United States Patent and Trademark Office Patents 1230(2)

Malan, T.P.; Ibrahim, M.M.; Lai, J.; Vanderah, T.W.; Makriyannis, A.; Porreca, F. 2003: CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?. Current Opinion in Pharmacology 3(1): 62-67

Lotersztajn, S.; Julien, B.; Grenard, P.; Li, L.; Mallat, A.; Davaille, J. 2003: CB2 receptors stimulate apoptosis of human hepatic myofibroblasts A novel antifibrogenic pathway in the liver?. FASEB Journal 17(4-5): Abstract 162

Usui, T. 2001: CB6F1-TgrasH2 mice Its profile and standard design for a 26-week alternative carcinogenicity study. Toxicologic Pathology 29(Suppl): 235

Nyberg, P.; Andersson, J.; Sunnemark, D.; Dahlstedt, A.; Westerblad, H.; Orn, A.; Lundberg, I. 2000: CBA/J mice infected with Trypanosoma cruzi as an experimental model for human polymyositis. Immunology Letters 73(2-3): 158

Freeman, G.L.Jr; Montesano, M.A.; Colley, D.G.; Secor, W.E. 1999: CBA/J mice infected with a single sex of Schistosoma mansoni cercariae express cross-reactive idiotypes on some anti-sea antibodies. American Journal of Tropical Medicine and Hygiene 61(3 Suppl): 498-499

Budde, U.; Schneppenheim, R.; Zieger, B.; Drewke, E.; Mainusch, K.; Bergmann, F.; Sutor, A. 1999: CBA/vWF Ag-ratio for diagnosis of von Willebrand disease Incorrect classification in more than 10% of patients with vWD type 2. Annals of Hematology 78(Suppl 1): A18

Gorenflo, V.M.; Pfeifer, T.A.; Grigliatti, T.A.; Lesnicki, G.; Kilburn, D.G.; Piret, J.M. 2001: CBD-Factor X fusion protein production by a stable transformed Sf9 insect cell line in a high cell density perfusion culture. Abstracts of Papers American Chemical Society 221(1-2): BIOT 147

Donlon, J.A. 1999: CBER: new approaches to biological product testing. Developments in Biological Standardization 101: 21-25

Marshall, R.S.; Lazar, R.M.; Duong, D.H.; Brunson, J.; Young, W.L.; Solomon, R.A.; Pile Spellman, J. 2000: CBF and enhanced clinical testing predict outcome after therapeutic internal carotid artery occlusion. Neurology 54(7 Supp 3): A63

Ihlow, K.; Hoppmann, S.; Hoeck, M.; Matzdorff, A.C.; Pralle, H.; Banat, G.Andre 2003: CBF beta positive acute myeloid leukemia cells induce T-cell responses. Blood 102(11): 611a

Preudhomme, C.; Warot Loze, D.; Leroy, H.; Imbert, M.; Eclache, V.; Davi, F.; Roumier, C.; Macintyre, E.; Berger, R.; Flandrin, G.; Fenaux, P. 2001: CBF mutations in myelodysplastic syndrome and undifferentiated acute myeloid leukemia. Leukemia Research 25(Suppl 1): S34

Chu, J.; Bresnick, E.H. 2003: CBF1 binding is required for Notch-1-mediated repression of activator protein-1. Blood 102(11): 573a-574a

Robinson, J.A.; Bhat, B.; Susulic, V.; Mangine, A.; Coleburn, V.; Bex, F. 2000: CBFA1 mediated induction of extracellular matrix protein expression in human osteoblastic cells is cell line dependent-evidence for CBFA2 and CBFA3 expression in multiple human osteoblastic cell lines. Journal of Bone and Mineral Research 15(Suppl 1): S497

Monroy, N.; Machuca Tzili, L.E.; Kofman, S. 2001: CBFA1 mutations and polymorphisms in two Mexican patients with cleidocranial dysplasia. American Journal of Human Genetics 69(4 Suppl): 607

Dauwerse, H.; Pirc Danoewinata, H.; Koenig, M.; Mittelbauer, M.; Simons, A.; Jaeger, U.; Breuning, M.H.; Haas, O.A. 2000: CBFB/MYH11 fusion in a patient with AML M4Eo, without the pericentric inversion of chromosome 16 Insertion or double inversion?. European Journal of Human Genetics 8(Suppl 1): 91

Boger, D.L. 2003: CBI analogs of CC-1065 and the duocarmycins. Official Gazette of the United States Patent and Trademark Office Patents 1269(3)

Sattler, M.; Pride, Y.B.; Gramlich, J.L.; Quinnan, L.R.; Salgia, R.; Lipkowitz, S.; Griffin, J.D. 2002: CBL-B Is a Negative Regulator of Transformation by BCR/ABL. Blood 100(11): Abstract No. 2290

Batistic, O.; Waadt, R.; Steinhorst, L.; Held, K.; Kudla, J.ör. 2010: CBL-mediated targeting of CIPKs facilitates the decoding of calcium signals emanating from distinct cellular stores. Plant Journal: for Cell and Molecular Biology 61(2): 211-222

Putnam,L.A.; Gambrell,R.P.; Rusch,K.A. 2010: CBOD5 treatment using the marshland upwelling system. Ecological Engineering: 4, 548-559

Mitra, S.S.; Barber, J.; Mason, M.D.; Allan, D.; Savage, P. 1999: CBOP/BEP chemotheraphy for intermediate and poor prognosis patients and relapsed patients with germ cell tumours. British Journal of Cancer 80(Suppl 2): 109

Suh, E.; Boudreau, F.; Wijesooriya, H.; Taylor, J.; Traber, P.G. 2002: CBP and PCAF-mediated acetylation enhanced transcriptional activation of Cdx2. Gastroenterology 122(4 Suppl 1): A 680

Leahy, P.; Chakravarty, K.; Gronostajski, R.M.; Hanson, R.W. 1999: CBP and nuclear factor I regulate P-enolpyruvate carboxykinase gene transcription. FASEB Journal 13(7): A1374

Blobel, G.A. 2002: CBP and p300: versatile coregulators with important roles in hematopoietic gene expression. Journal of Leukocyte Biology 71(4): 545-556

Yoon, J.W.; Iannaccone, P.M.; Walterhouse, D.O. 2000: CBP functions as a coactivator for the human oncogene GLI. Proceedings of the American Association for Cancer Research 41: 439

Nakazawa, M.; Hasunuma, T.; Nishioka, K.; Nakajima, T. 1999: CBP is a target molecule of HTLV-1 tax for synoviocyte activation. Arthritis and Rheumatism 42(9 Suppl): S200

Nemajerova, A.; Smarda, J.; Smardova, J. 2000: CBP is involved in regulation of differentiation of v-Myb-transformed monoblasts. Journal of Biomolecular Structure and Dynamics 17(6): 1177

Seewaldt, V.L.; Dietze, E.C.; Mrozek, K.; Caldwell, L.E.; Bean, G. 2002: CBP modulates resistance to reconstituted extracellular matrix-induced apoptosis in human mammary epithelial cells. International Journal of Cancer Suppl (13): 340

Bartsch, O.; Locher, K.; Meinecke, P.; Kress, W.; Pilz, M.; Ostermann, K.; Roedel, G. 2000: CBP mutation detection and genotype-phenotype correlation in patients with Rubinstein-Taybi syndrome and a woman with presumably a mild RTS variant and normal intelligence. American Journal of Human Genetics 67(4 Suppl 2): 15

Giles, R.H.; Dauwerse, J.G.; Blough, R.I.; Rus, A.M.; Van Ommen, G.J.B.; Peters, D.J.M.; Breuning, M.H.; Petrij, F. 1999: CBP mutation detection of the Rubinstein-Taybi syndrome for diagnostic purposes. American Journal of Human Genetics 65(4): A297

Chen, Q.; Dowhan, D.H.; Liang, D.C.; Moore, D.D.; Overbeek, P.A. 2001: CBP/p300 coactivation of c-maf-mediated crystallin gene expression is regulated by Prox-1 and Sox-1. IOVS Investigative Ophthalmology and Visual Science 42(4): S922

Song, S.H.; Jong, H.S.; Choi, M.C.; Park, J.A.; Bang, Y.J. 2003: CBP/p300-mediated Cyclooxygenase-2 induction is down-regulated by overexpression of wild-type p53 in human cancer cells. Proceedings of the American Association for Cancer Research 44: 1013-1014

Beger, C.; Pierce, L.; Krueger, M.; Westphal, S.; Robbins, J.; Welte, K.; Barber, J.; Wong Staal, F. 2002: CBR1 Identification and cloning of a novel gene involved in regulation of BRCA1 expression. Proceedings of the American Association for Cancer Research 43: 111

L.G.and, R.; Cheret, A.; Caufour, P.; Neildez, O.; Matheux, F.; Croitoru, J.; Vaslin, B.; Dormont, D. 1999: CC Chemokine PARC as a new surrogate marker of HIV disease progression Contribution of the SIV/macaque model. Journal of Medical Primatology 28(4-5): 294

Overall, C.M.; Mcquibban, G.A.; Clark Lewis, I.; Gong, N. 2002: CC and CXC tumor chemokines New members of the MMP degradome. Proceedings of the American Association for Cancer Research 43: 439

Carollo, M.; Christie, M.; Perretti, M. 1999: CC chemokine expression in a murine model of chronic granuloma. British Journal of Pharmacology 128(Proceedings Suppl ): 22P

Reiss, Y.; Campbell, J.J.; Butcher, E.C. 2000: CC chemokine receptor 4 and its ligand TARC in lymphocyte trafficking to the inflamed skin. Immunobiology 203(1-2): 303

Vermeire, S.; Rector, A.; Joossens, S.; Thoelen, I.; Keyaerts, E.; Struyf, F.; Van Ranst, M.; Rutgeerts, P. 2000: CC chemokine receptor 5 and serological markers ASCA and pANCA in inflammatory bowel disease. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1375

Gonzalez, E.; Wiley, H.; Hwang, S. 2001: CC chemokine receptor 7 -transduced B16 melanoma cells show enhanced early metastases to regional lymph nodes. Journal of Investigative Dermatology 117(2): 483

Pertosa, G.; Grandaliano, G.; Gesualdo, L.; Soccio, M.; Schena, F.P. 2001: CC chemokine receptor-2 gene expression in peripheral blood mononuclear cells from uremic patients Modulation by different dialytic membranes. Nephrology Dialysis Transplantation 16(6): A186

Mcmanus, C. 1999: CC chemokines and their receptors Role in central nervous system pathologies. Einstein Quarterly Journal of Biology and Medicine 16(4): 192-201

Saito, N.; Yamada, Y.; Sannohe, S.; Chang Hao, C.; Kanda, A.; Yamaguchi, K.; Hamada, K.; Chihara, J. 2002: CC chemokines as augmentative agents for eosinophil adhesion. International Archives of Allergy and Immunology 128(Suppl 1): 25

Galia, L.; Sima, S.; Ofer, K.; Santiago, E.; Devora, N.; Beatriz, L.M.; Samario, C.; Iafa, K.; Adit, B.B. 2000: CC chemokines as potential regulators of breast cancer progression. International Journal of Molecular Medicine 6(Suppl 1): S71

Zhao, R.Y.; Chari, R.V.J. 2003: CC-1065 analog synthesis. Official Gazette of the United States Patent and Trademark Office Patents 1272(1)

Sorbera, L.A.; Castaner, J.; Bayes, M. 2003: CC-5013 Treatment of multiple myeloma, treatment of melanoma, treatment of myelodysplastic syndrome, angiogenesis inhibitor, TNF-alpha production inhibitor. Drugs of the Future 28(5): 425-431

Mangia, A.; D'agruma, L.; Gasparini, P.; Zelante, L.; Cascavilla, I.; Conoscitore, P.; Andriulli, A. 1999: CC-CKR5 gene deletion influences the course of HCV chronic infection. European Journal of Human Genetics 7(Suppl 1): 61

Anders, H.J.; Vielhauer, V.; Segerer, S.; Luckow, B.; Groene, H.J.; Schloendorff, D. 1999: CC-Chemokine and -receptor expression during immune-complex glomerulonephritis in mice. Kidney and Blood Pressure Research 22(4-6): 214

Vielhauer, V.; Anders, H.J.; Weller, L.; Grone, H.J.; Luckow, B.; Strutz, F.; Schlondorff, D. 2000: CC-chemokine and -receptor expression during progressive renal fibrosis in murine obstructive nephropathy. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 484A

Arreaza, G.A.; Cameron, M.J.; Grattan, M.; Bergerot, I.; Delovitch, T.L. 1999: CC-chemokine expression in the islets of NOD mice Role as modulators of insulitis and diabetes onset. FASEB Journal 13(4 Part 1): A286

Kalev, I.; Oselin, K.; Parlist, P.; Podar, T.; Mikelsaar, A. 2001: CC-chemokine receptor CCR5 gene polymorphism analysis in diabetes type I and type II patients in Estonia. European Journal of Human Genetics 9(Suppl 1): P0867

Ellingsen, T.; Moller, B.K.; Herlin, T.; Damsgaard, T.; Stengaard Pedersen, K. 1999: CC-chemokines, -chemokine receptors, T-cell and monocyte activation markers in juvenile idiopathic arthritis. Arthritis and Rheumatism 42(9 Suppl): S181

Lindfors, K.; Halttunen, T.; Kainulainen, H.; Maki, M. 2000: CC3/TIP30 and rab11 Novel markers for in vitro and in vivo intestinal epithelial cell differentiation. JPGN 31(Suppl 2): S75

Tobin, E.M.; Andronis, C.; Green, R.M.; Ong, M.S.; Sugano, S. 1999: CCA1 is a transcription factor associated with circadian rhythms. Plant Biology (Rockville) : 23

Teng, X.; Li, D.; Johns, R.A. 2001: CCAAT box enhancer binding protein beta mediates hypoxia-enhanced inducible nitric oxide synthase expression in rat pulmonary microvascular smooth muscle cells. FASEB Journal 15(5): A761

Snyder, S.R.; Waring, J.F.; Wang, J.; Ginder, G.D. 1999: CCAAT displacement protein mediates locus-specific repression of HLA-B7 gene expression in tumor cells. Proceedings of the American Association for Cancer Research 40: 513

Greenbaum, L.E.; Kovalovich, K.; Taub, R.; Ciliberto, G.; Poli, V. 2000: CCAAT enhancer binding protein beta is required for Fas-induced apoptosis in liver. Gastroenterology 118(4 Suppl 2 Pt 1): AASLD A962